

Surveillance of COVID-19 in a Vaccinated Population

A Rapid Literature Review

Date of Literature Search: 6/14/2021 Date of Submission: 6/25/2021

Prepared By:

Oluwaseun Egunsola, Brenlea Farkas, Jordyn Flanagan, Charleen Salmon, Liza Mastikhina, Fiona Clement, on behalf of the University of Calgary Health Technology Assessment Unit.

Contact:

Fiona Clement

Email: fclement@ucalgary.ca

Suggested citation: : Egunsola O, Farkas B, Flanagan J, Salmon C, Mastikhina L, Clement FM on behalf of the University of Calgary Health Technology Assessment Unit. Surveillance of COVID-19 in a Vaccinated Population: A Rapid Literature Review. June 25, 2021



UNIVERSITY OF CALGARY





Funding Acknowledgement(s)

The SPOR Evidence Alliance (<u>SPOR EA</u>) is supported by the Canadian Institutes of Health Research (<u>CIHR</u>) under the Strategy for Patient-Oriented Research (<u>SPOR</u>) initiative.

COVID-19 Evidence Network to support Decision-making (<u>COVID-END</u>) is supported by the Canadian Institutes of Health Research (<u>CIHR</u>) through the Canadian 2019 Novel Coronavirus (COVID-19) Rapid Research Funding opportunity.

Project Contributors

Oluwaseun Egunsola^{1,2}; Brenlea Farkas^{1,2}; Jordyn Flanagan^{1,2}, Charleen Salmon^{1,2}, Liza Mastikhina^{1,2}; and Fiona Clement^{1,2}

Affiliations

- 1. The Department Community Health Sciences, Teaching Research and Wellness Building, 3280 Hospital Drive NW Calgary Alberta T2N 4N1
- 2. O'Brien Institute for Public Health, Teaching Research and Wellness Building, 3280 Hospital Drive NW Calgary Alberta T2N 4N1

Third-Party Materials

If you wish to reuse non-textual material from this report that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is required for such use and to obtain necessary permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned material rests solely with the user.

General Disclaimer

This report was prepared by the University of Calgary Health Technology Assessment Unit on behalf of the SPOR Evidence Alliance and COVID-END. It was developed through the analysis, interpretation and synthesis of scientific research and/or health technology assessments published in peer-reviewed journals, institutional websites and other distribution channels. It also incorporates selected information provided by experts and patient/citizen partners with lived experience on the subject matter. This document may not fully reflect all the scientific evidence available at the time this report was prepared. Other relevant scientific findings may have been reported since completion of this synthesis report.

SPOR Evidence Alliance, COVID-END and the project team make no warranty, express or implied, nor assume any legal liability or responsibility for the accuracy, completeness, or usefulness of any information, data, product, or process disclosed in this report. Conclusions drawn from, or actions undertaken on the basis of, information included in this report are the sole responsibility of the user.



Table of Contents

Abbreviations and Definitions	3
Abbreviations	3
Key Definitions:	3
ABSTRACT	4
EXECUTIVE SUMMARY	6
Introduction	9
Section 1: Scientific Evidence on Surveillance Methods in a Vaccinated Population	0
Methods1	0
Results1	1
Surveillance Methods for COVID-19 Cases	3
Discussion2	9
Section 2: International Guidance on Surveillance Methods in a Vaccinated Population	0
Methods	0
Results3	1
Vaccine-Specific Surveillance	1
Discussion4	1
Conclusions	2
References 4	3
Appendix A: Search Strategies for Scientific Evidence of Surveillance	8
Appendix B: Additional Details on International Guidance	5



Abbreviations and Definitions

Abbreviations

CDC	Centres for Disease Control and Prevention
COVID-19	Coronavirus Disease 2019
VOC	Variant of concern
WHO	World Health Organization
RT-PCR	Reverse transcriptase polymerase chain reaction
ECDC	European Centre for Disease Prevention and Control

Key Definitions:

Antigen: a foreign protein which induces an immune response in the body, especially the production of antibodies

Fully vaccinated: refers to individuals who have received complete dosage of a given vaccine

Partially vaccinated: refers to individuals who have received an incomplete dosage of a given vaccine

Sero-surveillance: estimation of antibody levels against infectious diseases

Surveillance: ongoing systematic collection, analysis, and interpretation of health data that are essential to the planning, implementation, and evaluation of public health practice

Variants of Concern: a variant for which there is evidence of an increase in transmissibility and/or more severe disease

Variants: virus with a permanent change in its genetic sequence



ABSTRACT

Objectives: With the availability of COVID-19 vaccines, public health focus is shifting to post-vaccination surveillance to identify breakthrough infections in vaccinated populations. Therefore, the objectives of these reviews are to identify scientific evidence and international guidance on surveillance and testing approaches to monitor the presence of the virus in a vaccinated population.

Method: We searched Ovid MEDLINE®, including Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Embase, EBM Reviews - Cochrane Central Register of Controlled Trials, and EBM Reviews - Cochrane Database of Systematic Reviews. We also searched the Web of Science Core Collection. A grey literature search was also conducted. This search was limited to studies conducted since December 2020 and current to June 13th, 2021. There were no language limitations. COVID-19 surveillance studies that were published after December 2020 but did not specify whether they tested a vaccinated population were also considered for inclusion.

For the international guidance review, a grey literature search was conducted, including a thorough search of Google, websites of international government organizations (e.g., Center for Disease Control and Prevention [CDC], World Health Organization [WHO]), and McMaster Health Forum (CoVID-END). This search was primarily examining surveillance guidance published since December 2020 (to capture guidance specific to vaccinations) and any relevant pre-December 2020 guidance.

Results: Thirty-three studies were included for data synthesis of scientific evidence on surveillance of COVID-19. All the studies were published between April and June 2021. Twenty-one studies were from peer-reviewed journals. Five approaches to monitoring post-vaccination COVID-19 cases and emerging variants of concern were identified, including screening with reverse transcriptase polymerase chain reaction (RT-PCR) and/or a rapid antigen test, genomic surveillance, wastewater surveillance, metagenomics, and testing of air filters on public buses. For population surveillance, the following considerations and limitations were observed: variability in person-to-person testing frequency; lower sensitivity of antigen tests; timing of infections relative to PCR testing can result in missed infections; large studies may fail to identify local variations; and loss of interest in testing by participants in long follow-up studies.

Through comprehensive grey literature searching, 68 international guidance documents were captured for full-text review. A total of 26 documents met the inclusion criteria and were included in our synthesis. Seven overarching surveillance methods emerged in the literature. PCR-testing was the most recommended surveillance method, followed by genomic screening, serosurveillance, wastewater surveillance, antigen testing, health record screening, and syndromic surveillance.

Conclusion: Evidence for post-vaccination COVID-19 surveillance was derived from studies in partially or fully vaccinated populations. Population PCR screening, supplemented by rapid antigen tests, was



the most frequently used surveillance method and also the most commonly recommended across jurisdictions. Most recent guidance on COVID-19 surveillance is not specific to vaccinated individuals, or it is in effect but has not yet been updated to reflect that. Therefore, more evidence-informed guidance on testing and surveillance approaches in a vaccinated population that incorporates all testing modalities is required.



EXECUTIVE SUMMARY

Objectives: With the availability of COVID-19 vaccines, public health focus is shifting to postvaccination surveillance to identify breakthrough infections in vaccinated populations. Therefore, the objectives of these reviews are to: 1) identify scientific evidence on surveillance and testing approaches to monitor the presence of the virus in a vaccinated population and determine how these influence testing strategies; 2) identify international guidance on testing and surveillance for COVID-19 and its variants of concern in a vaccinated population; and 3) identify emerging technologies for surveillance.

Design: A rapid review was conducted to identify scientific evidence on COVID-19 surveillance and testing approaches, and a targeted literature review was conducted on international guidance.

Method: We searched Ovid MEDLINE®, including Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Embase, EBM Reviews - Cochrane Central Register of Controlled Trials, and EBM Reviews - Cochrane Database of Systematic Reviews. We also searched the Web of Science Core Collection. We performed all searches on June 13, 2021. A grey literature search was also conducted, including: MedRxiv, Google, McMaster Health Forum (COVID-END), and websites of international government organizations (e.g., Center for Disease Control and Prevention [CDC], World Health Organization [WHO]). This search was limited to studies conducted since December 2020 and current to June 13th, 2021. There were no language limitations. COVID-19 surveillance studies that were published after December 2020 but did not specify whether they tested a vaccinated population were also considered for inclusion.

For the international guidance review, a grey literature search was conducted, including a thorough search of Google, websites of international government organizations (e.g., Center for Disease Control and Prevention [CDC], World Health Organization [WHO]), and McMaster Health Forum (CoVID-END). This search was primarily examining surveillance guidance published since December 2020 (to capture guidance specific to vaccinations) and any relevant pre-December 2020 guidance. Although the primary focus was on surveillance guidance in a vaccinated population, guidance that was published after December 2020 but was not vaccine-specific was also considered for inclusion; it was assumed that this guidance was still in effect and was not yet updated. There were no language limitations. A patient partner was engaged during the co-production of a plain language summary for both the rapid review of primary literature and the review of international guidance.

Results: Thirty-three studies were included for data synthesis of scientific evidence on surveillance of COVID-19. All the studies were published between April and June 2021. Twenty-one studies were from peer-reviewed journals. Five approaches to monitoring post-vaccination COVID-19 cases and emerging variants of concern were identified including, screening with reverse transcriptase polymerase chain reaction (RT-PCR) and/or a rapid antigen test, genomic surveillance, wastewater surveillance, metagenomics, and testing of air filters on public buses. Population surveillance with RT-PCR testing



and/or rapid antigen testing was utilized in 22 studies, mostly in healthcare settings, but also in longterm care facilities (LTCFs) and in the community. The frequency of testing varied depending on whether there was an outbreak.

For population surveillance, the following considerations and limitations were observed: studies with discretionary access to testing have highly variable person-to-person testing frequency; antigen tests have lower sensitivity, therefore some positive cases may be missed; timing of infections relative to PCR testing as well as the sensitivity of the tests can result in missed infections; large sample sizes from multicentre studies increase generalizability, but fail to identify local variations from individual centres; with electronic database surveillance, it is difficult to confirm whether patients with a breakthrough infection and a previous positive SARS-CoV-2 test result had a true reinfection or had prolonged shedding from the previous infection; and participants lose interest in studies with long follow-up, with decrease in testing rates over time.

Six wastewater surveillance and three genomic surveillance studies were identified in this review. A number of benefits such as, good correlation with clinical data, ability to predict major outbreaks, and rapid turnaround time were observed with wastewater surveillance. However, challenges such as, inconsistencies in variant representation depending on where the samples were taken within the community, differences in the capacity of wastewater to predict case numbers based on the size of the wastewater treatment plants, and cost, were noted. Emerging technologies like viral detection in public transport filters, novel sampling, and assay platforms were also identified.

Through comprehensive grey literature searching, 68 international guidance documents were captured for full-text review. A total of 26 documents met the inclusion criteria and were included in our synthesis. Most were not specific to vaccinated populations but reported on a surveillance method of COVID-19 and were therefore included in the review; it was assumed that they were still in effect but have not yet been updated. Eleven countries/regions were represented, including Australia, Brazil, France, Germany, India, New Zealand, Spain, United Kingdom, United States, Europe, and International. All of the guidance documents included surveillance methods appropriate for community settings. Other settings of interest were healthcare settings, including hospitals and primary care centres, long-term care facilities, points of entry for travel, schools, and other sentinel sites (e.g., prisons and closed settings). Seven overarching surveillance methods emerged in the literature. PCR-testing was the most recommended surveillance, antigen testing, health record screening, and syndromic surveillance.

Only one document (published by Public Health England) was identified that provided guidance on surveillance specific to vaccinated populations. The document outlined a plan to surveil and monitor COVID-19 in vaccinated populations through a series of targeted longitudinal studies, routine surveillance, enhanced surveillance, use of electronic health records, surveillance of vaccine failure



(including follow-up with viral whole genome sequencing), and sero-surveillance (including blood donor samples, routine blood tests, and residual sera).

Conclusion: Evidence for post-vaccination COVID-19 surveillance was derived from studies in partially or fully vaccinated populations. Population PCR screening, supplemented by rapid antigen tests, was the most frequently used surveillance method and also the most commonly recommended across jurisdictions. The selection of testing method and the frequency of testing was determined by the intensity of the disease and the scale of testing. Other common testing methods included wastewater surveillance and genomic surveillance. A few novel technologies are emerging, however, many of these are yet to be utilized in the real-world setting. There is limited evidence-based guidance on surveillance in a vaccinated population. Most recent guidance on COVID-19 surveillance is not specific to vaccinated individuals, or it is in effect but has not yet been updated to reflect that. Therefore, more evidence-informed guidance on testing and surveillance approaches in a vaccinated population that incorporates all testing modalities is required.

Protocol/Topic Registration: PROSPERO-CRD42021261215.



Introduction

Coronavirus disease (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). As of June 2021, there have been more than 179,000,000 confirmed cases of COVID-19, which have resulted in more than 3,800,000 confirmed deaths worldwide.¹ Numerous randomized controlled trials (RCTs) and real-world observational studies have found vaccines to be safe and effective at preventing COVID-19.² At the time of writing, more than 2,700,000 vaccine doses have been administered across the world, with several countries (e.g., Israel, the UK) approaching the 70% benchmark of having their population fully vaccinated with the goal of reaching herd immunity.^{1,3}

As the number of partially and fully vaccinated people continues to grow, countries may be pivoting their population-level surveillance methods to capture the presence and resurgence of COVID-19 and its variants of concern (VOCs). RT-PCR testing of nose and throat swabs is a widely used method to identify new cases of COVID-19; however, the ability of RT-PCR testing to slow viral spread may be impacted by slow laboratory turnaround times and restricted availability of the tests.⁴ As a result, there may be interest in alternative population-level testing modalities that can detect the presence and resurgence of the virus in a setting before an outbreak.

This rapid review aims to answer the following research questions:

- What scientific evidence exists on surveillance approaches to monitor the presence of the virus in a fully vaccinated population (i.e., monitoring for resurgence and variants of concern through wastewater surveillance and metagenomics, population screening with rapid antigen testing)? How does this influence testing strategies?
 - a. What technologies are emerging to identify infection caused by variants of concern in a vaccinated population?
- 2. What international guidance exists on testing and surveillance for SARS-CoV-2 and its variants of concern in a fully vaccinated population?

Recognizing that the evidence on surveillance in fully vaccinated populations may be limited, this review also includes literature assessing surveillance broadly in a partially vaccinated population to ensure that all relevant literature is captured.



Section 1: Scientific Evidence on Surveillance Methods in a Vaccinated Population

Methods

This rapid review is registered in the International Prospective Register of Systematic Reviews (PROSPERO), number CRD42021261215. An experienced medical information specialist developed and tested the search strategies through an iterative process in consultation with the review team. Another senior information specialist peer reviewed the MEDLINE strategy prior to execution using the PRESS Checklist.⁵ Using the multifile option and deduplication tool available on the OVID platform, we searched Ovid MEDLINE®, including Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Embase, EBM Reviews - Cochrane Central Register of Controlled Trials, and EBM Reviews - Cochrane Database of Systematic Reviews. We also searched the Web of Science Core Collection. We performed all searches on June 13, 2021.

The strategies utilized a combination of controlled vocabulary (e.g., "COVID-19", "Epidemiological Monitoring", "Population Surveillance") and keywords (e.g., "nCoV", "vaccinated", "surveillance"). Vocabulary and syntax were adjusted across the databases (full search strategies included in Appendix A). No language restrictions were applied but results were limited to the publication years 2020 to the present. Results were downloaded and deduplicated using EndNote version 9.3.3 (Clarivate Analytics) and uploaded to Microsoft Word.

A grey literature search was also conducted, including: MedRxiv, Google, McMaster Health Forum (CoVID-END), and websites of international government organizations (e.g., Center for Disease Control and Prevention [CDC], World Health Organization [WHO]). This search was limited to studies conducted since December 2020 and current to June 13th, 2021. There were no language limitations.

A screening form based on the eligibility criteria was prepared. Citations identified as potentially relevant from the literature search were screened by single reviewer across a team of four reviewers and subsequently read in full text by two reviewers and assessed for eligibility based on the criteria outlined below (Table 1). Discrepancies were resolved by discussion or by a third reviewer. Reference lists of included studies were hand searched to ensure all relevant literature is captured.

Table 1. Criteria for Inclusion of Scientific Evidence on Surveillance

Population	Persons who have been partially or fully vaccinated against COVID-19;
	populations in settings with a high vaccination rate/low prevalence rate of
	COVID-19 and low vaccination rate/low prevalence rate of COVID-19 were
	also considered



Intervention	Surveillance approaches to monitor for resurgence of COVID-19 and variants of concern (e.g., wastewater surveillance and metagenomics, population screening with rapid antigen testing)
Comparator	No comparator required
Outcome	Any
Study Design	Observational studies examining a surveillance approach to monitor for resurgence of COVID-19 and variants of concern; non-interventional designs like editorials, opinions, reviews were excluded
Publication Year	Limited to publication date or data collected December 2020-onwards

A standardized data extraction sheet was used to extract the month and year of publication, country, study design, surveillance method, variant surveillance, dates of enrollment, vaccination status, population, setting, primary outcomes, and implementation considerations. All reviewers completed a calibration exercise whereby data from two sample studies were extracted by all four reviewers and areas of disagreement were discussed. Data were extracted by one reviewer.

Given the rapid nature of this request, a formal risk of bias assessment was not conducted. A high-level discussion of quality of the evidence (i.e., peer-reviewed vs. preprints) is included below.


Due to the heterogeneity in study designs and outcomes across included studies, data were synthesized narratively; a meta-analysis was not conducted. A high-level summary of the different surveillance methods, populations assessed by the methods, and outcomes is presented in the next section. A patient partner was engaged during the co-production of a plain language summary, which is presented in a separate document.

Results

A total of 1197 articles were identified from database search. After removing duplicates, 914 unique citations were included; 90 of which were assessed in full text articles. Thirty-three studies were included for data synthesis (Figure 1). All the studies were published between April and June 2021. Thirteen were national studies; there were seven regional and city-wide studies each; five were single-centre studies (e.g., hospitals and long-term care facilities [LTCFs]); and one was an international study. Sixteen studies were conducted in the USA, four were from England, three each from Israel and Spain, two from Italy, and one study from each of the following: the UK, Canada, India, Indonesia, and Uruguay. The majority of the studies (n=21) were from peer-reviewed journals (Table 2).










Surveillance Methods for COVID-19 Cases

Five approaches to monitoring post-vaccination COVID-19 cases and emerging variants of concern were identified in this review. These include population screening with reverse transcriptase polymerase chain reaction (RT-PCR) and or a rapid antigen test, genomic surveillance, wastewater surveillance, metagenomics, and testing of air filters on public buses (

Figure 2).

Figure 2: Summary of Scientific Evidence on Surveillance Methods





Population Screening with RT-PCR and or Rapid Antigen Testing

RT-PCR testing and or rapid antigen testing was utilized in 22 studies. The majority of these studies were in healthcare settings (10 studies), seven were in LTCFs, and two in the community. In two studies, surveillance was conducted among healthcare and essential workers, while another two studies involved LTCFs and the community (Table 2).

Healthcare Setting

The studies involving healthcare workers (HCWs) were mostly conducted at single hospitals (7 studies); while two studies were national,^{6,7} and one was a regional study.⁸ In some studies, routine post-exposure screening of symptomatic or asymptomatic HCWs using RT-PCR based testing of samples obtained from nasal or oropharyngeal swabs were implemented;⁹⁻¹² while some other studies implemented periodic (typically weekly) asymptomatic screenings.^{6,13-15} Although the majority of the surveillance involving HCWs utilized only RT-PCR testing, two studies used a combination of RT-PCR and rapid antigen testing. One was a biweekly national surveillance study of HCWs in England,⁷ and the other was at a single hospital in India.¹⁶ Seven of the hospital-based studies also implemented genetic sequencing to identify variants following a positive RT-PCR test. All the studies identified breakthrough cases among vaccinated individuals, some sequenced for VOCs, while also demonstrating the effectiveness of vaccination against infections.

Long Term Care Facilities

There were four national LTCFs studies,¹⁷⁻²⁰ two regional studies^{21,22} and one city-wide study.²³ Five of the seven LTCF surveillance studies utilized RT-PCR and or rapid antigen testing.^{18,20-23}

The frequency of testing appeared to vary depending on whether there was an outbreak. In one study involving LTCFs in Catalonia, Spain, the public health guidelines required routine two-to-four weekly screening of residents and staff with RT-PCR or antigen tests,²¹ another study reported two weekly screenings in the absence of an outbreak with an additional daily rapid antigen testing (with confirmatory RT-PCR for positive tests) during an outbreak.²² Other studies reported a more frequent screening schedule varying between five-to-seven days during an outbreak.^{18,19} Of note, one national USA study reported that the Centres for Medicare and Medicaid services required all nursing homes in the same county to test all their staff and residents at the same frequency based on the county COVID-19 rate.¹⁷ A number of the LTCF studies conducted genetic sequencing to identify variants.^{19,22} Although breakthrough cases were found among vaccinated individuals, the studies generally demonstrated the effectiveness of vaccination in the prevention of infection.

Community



The two community-based population surveillance studies identified in this review were national studies and were conducted in Israel and England.^{24,25} The English study utilized self-administered throat and nose swabs and questionnaire data from a random sample of the population ages 5 years and above. From this study, it was observed that 92.3% of infections in England at the time were from the B.1.1.7 lineage and 7.7% from the B.1.617.2 lineage.²⁴ The Israeli national study conducted surveillance in LTCFs and the community (using samples from random drive-through testing centres)²⁶ and showed that the B.1.1.7 variant was 45% more transmissible than the wild-type strain in Israel. These studies identified COVID-19 cases among vaccinated individuals, and also determined the prevalence and transmissibility of variants.

Implementation Considerations and Limitations of Population Surveillance

The following implementation considerations for and limitations to population surveillance were identified in the reviewed studies:

- 1. For studies allowing discretionary access to testing, the frequency of testing tends to be highly variable from person to person.¹²
- 2. Antigen tests have lower sensitivity, therefore some positive cases may be missed during asymptomatic screening.⁹
- 3. The timing of infections relative to PCR testing and the sensitivity of the PCR tests can result in infections being missed during follow-up.⁷
- 4. While large sample sizes from multicentre studies increase generalizability, several studies observed that details of local variation in practices (in healthcare settings or long-term care facilities) are lost when findings from different centres are pooled and analyzed together. Therefore, the findings of such studies may not be generalizable.¹⁹⁻²¹ For example, the Centres for Medicare and Medicaid Services in the USA required all nursing homes to test residents and staff at the same frequency dictated by the rate of COVID-19 in the community (not in the facility).¹⁷
- 5. Teran et al noted that, with electronic databases, it was impossible to confirm whether patients with a breakthrough infection and a previous positive SARS-CoV-2 test result had a true reinfection or had prolonged shedding from the previous infection.²³
- 6. In a study with prolonged follow up period, the authors observed a progressive decline in participants' interest.²⁴

Genomic Surveillance

Three genomic surveillance studies were identified in this review.^{27,28} Two were city-wide surveillance studies conducted in the USA,^{27,29} and one was a national scale study conducted in Uruguay.²⁸ All three were community-based studies. Two of the studies identified the emergence of variants in the communities. The Uruguayan national genomic surveillance study, for example, showed that variant P.1



was introduced in Uruguay at multiple times over a period of increasing mobility.²⁸ Similarly, Wang et al. demonstrated the rapid emergence of L452R mutation in the San Francisco Bay Area population, with a prevalence of 24.8% in December 2020 that increased to 62.5% in March 2021.²⁹

Wastewater surveillance

There were six wastewater surveillance studies: two were from Spain^{30,31} and the USA^{32,33}, respectively, and one each from Canada³⁴ and the UK.³⁵ The frequency of wastewater sampling varied between once a week^{30,32,35} to three times a week.³⁴

A number of benefits of wastewater surveillance were noted across studies. In Spain,³¹ wastewater surveillance predicted major outbreaks by several weeks and showed good correlation with clinical data, providing information at local level;³⁰ while another study in the USA reported a rapid turnaround time (average of 1.6 days).³² The challenges observed included: inconsistencies in variant representation depending on where the samples were taken within the community³³ and differences in the capacity of wastewater to predict case numbers based on the size of the wastewater treatment plants.³⁵ One study reported that laboratory build-out costs approximately \$100,000 USD in capital equipment and took 3 months to complete.³²

Testing Air Filters on Public Buses

In one study, Hoffman et al. placed and retrieved filters in the existing air filtration systems on public buses in Seattle to test for the presence of trapped SARS-CoV-2 RNA using phenol-chloroform extraction and RT-PCR. The study detected SARS-CoV-2 RNA in 14% of public bus filters tested.³⁶

Metagenomics

Using the nextstrain.org database, Quinonez et al. were able to predict that the rate of B.1.1.7 lineage is going to sharply decrease (near to zero) in the coming months. The authors suggested a cautious generalizability because of the lack of validation of this approach in an experimental study.³⁷

Emerging Technologies

New surveillance technologies for COVID-19 are emerging and some of these have been validated, but not yet studied in a real-world setting. Examples include the use of wearable monitoring device to continuously monitor skin temperature, heart rate, and respiratory rate for early detection of COVID-19 symptoms³⁸ and the use of deep learning-based model to detect COVID-19 infection via CT scans and chest X-rays.³⁹ A number of new assay methods (Table 3) and novel sample collection methods were also identified in this review; however, not all met inclusion criteria and were therefore not included in the broader synthesis. For example, Reeves et al. described a composite autosampler that withdraws samples from wastewater outfall within surface-accessible manholes that can be used to monitor and detect SARS-CoV-2 in individual buildings and communities.⁴⁰





Table 2: Surveillance Studies Involving Vaccinated Populations

Author (Country)	Setting/Scope	Surveillance method	Highlights from Surveillance
Population RT-	PCR or Rapid Antigen Scree	ning	
Angel et al ¹² (Israel) Peer - Reviewed	Healthcare/Single Hospital	Routine screening of HCWs with potential exposure using nasopharyngeal swabs and RT-PCR based virus detection	This was a retrospective cohort study involving fully vaccinated populations. The frequency of testing varied from person to person and health workers were able to access testing at their discretion. No variant surveillance was conducted.
Baj et al. ¹¹ (Italy) Peer-Reviewed	Healthcare/Single Hospital	Nasopharyngeal swabs of HCWs with RT-PCR testing. Testing frequency not reported.	This was a passive surveillance study describing a series of 11 voluntarily reported cases in fully vaccinated individuals. Spike gene sequencing showed they tested positive for different strains with 7 of 11 testing for B.1.1.7 (x7 patients) variant.
Bouton et al. ¹⁰ (USA) Preprint	Healthcare/Single Hospital	Asymptomatic RT-PCR testing was available to HCWs for workplace exposures, following out-of-state travel, and per request. 68 single nucleotide variants identified post at least one dose vaccine	This was a prospective cohort study of partial and fully vaccinated individuals showing a positive impact of COVID-19 vaccines on SARS-CoV-2 case rates was seen. Postvaccination isolates did not show unusual genetic diversity or selection for mutations of concern. Variant surveillance found no early evidence of specific spike mutations or mutations associated with neutralizing vaccine escape.
Cucunawangsi h et al. ⁹ (Indonesia) Grey Literature (Report)	Healthcare/Single Hospital	Symptomatic and post-exposure RT- PCR and antigen testing of HCWs	This was a retrospective study involving fully vaccinated individuals. Through passive and active surveillance, breakthrough cases were identified in 13 of the 1040 fully vaccinated HCWs. Because of the reduced sensitivity of antigen testing in asymptomatic populations, it was possible that some asymptomatic cases were not identified.
Hall et al ⁷ (England)	Healthcare/National	Twice weekly rapid antigen testing of HCWs per government guidelines. RT-	This was a prospective cohort study in partial or fully vaccinated individuals. It was possible that infections







Author (Country)	Setting/Scope	Surveillance method	Highlights from Surveillance
Peer-Reviewed		PCR testing of anterior nasal swabs or combined nose and oropharyngeal swabs every 2 weeks and monthly antibody testing.	were missed during follow-up, depending on timing of infection relative to PCR testing and PCR sensitivity.
Jacobson et al ⁶ (USA)	Healthcare/National	Self-monitoring for symptoms. If symptoms were present, RT-PCR testing was conducted. Some HCWs	This is a retrospective cohort study of partially vaccinated individuals. The great majority of post-vaccine SARS-COV-2 occurred prior to the expected
Preprint		participated in voluntary weekly asymptomatic RT-PCR testing.	onset of full, vaccine-derived immunity.
Jones et al ¹⁵ (England)	Healthcare/Single Hospital	HCWs or HCW household member could self-refer for RT-PCR testing if symptoms develop. HCWs had weekly	This was a retrospective cohort study of partially vaccinated individuals. Investigating asymptomatic infections means that the date of infection could be
Peer-Reviewed		asymptomatic testing at temporary on- site 'Pods' and via oropharynx and anterior nasal cavity self-swabbing.	earlier than the test date for the virus.
Sansone et al. ⁸ (Italy)	Healthcare/Regional	RT-PCR testing on rhino-pharyngeal swabs, followed by gene sequencing in positive vaccinated HCWs. Testing	This was a retrospective cohort study conducted when 78% of the workforce had been fully vaccinated, while a recrudescent wave of the SARS-
Peer Reviewed		frequency not reported.	CoV-2 pandemic hit Lombardy and particularly the Brescia County, where the B.1.1.7 variant was highly prevalent.
Tyagi et al. ¹⁶ (India) Peer-Reviewed	Healthcare/Single Hospital	RT-PCR and rapid antigen testing. Testing frequency not reported.	A passive surveillance approach was utilized in order to detect breakthrough cases following 94% full vaccination of work-force. There was no report on variant surveillance
Tang et al. ¹³ (USA) Peer-Reviewed	Healthcare/Single Hospital	Asymptomatic RT-PCR testing of mid- turbinate samples of hospital employees performed at least weekly	This was a prospective cohort study in partially or fully vaccinated individuals. The follow-up time was short.
Lutrick et al. ¹⁴ (USA)	Healthcare and Essential workers/Regional	Weekly RT-PCR testing of mid-turbinate samples. If participant experiences self-	Participants were prompted to provide samples at regular intervals via SMS. The study is ongoing with







Author (Country)	Setting/Scope	Surveillance method	Highlights from Surveillance
Preprint		reported symptoms, asked to provide additional nasal swab specimen. Each week, all participants were contacted via text message on their predesignated surveillance day. At the end of each text message exchange, the participant was reminded to collect a weekly specimen on their assigned day for collection.	no findings yet. The population of fully vaccinated Arizonans at the time of publication was not reported. Outcomes and generalisability could likely be biased due to healthy worker effect. Information from participants is self-reported or self-collected, therefore possible recall bias may be present.
Thompson et al ⁴¹ (USA) Peer-Reviewed	Healthcare and Essential workers/National	Self-collected a mid-turbinate nasal swab weekly, regardless of COVID-19– associated illness symptom status. Collected an additional nasal swab and saliva specimen at the onset of COVID- 19–associated illness for RT- PCR and antigen testing	An active symptom surveillance preceded nasal swabbing. Study was a longitudinal cohort conducted in eight cities across the USA. The cities were expected to have varying vaccination rates (not reported).
Rudolph et al ²⁰ (USA) Peer-Reviewed	Long Term Care/National	RT-PCR and rapid antigen testing. Testing frequency not reported, but positive cases were summarized weekly.	This was a retrospective cohort analysis of 130 department of veteran affairs community living centres (CLCs). The community nursing home data are self-reported, but do not report on the testing and vaccination practices of nursing homes. There are also major differences in patient populations between VA CLCs and CMS-certified nursing homes. Staff vaccination data was lacking. The large geographic spread of the VA system allowed a nationwide sampling but limited the detail on local variation in practices.
De Salazar et al ²¹ (Spain)	Long Term Care/Regional	All contacts among staff and residents were screened using molecular test (PCR or antigen test) immediately upon confirmation of an index infection in a	This was a retrospective study of fully vaccinated individuals. Analysis was conducted at county level rather than facility-level.
Preprint		facility; further, all staff and residents were regularly screened independently	







Author (Country)	Setting/Scope	Surveillance method	Highlights from Surveillance
		of whether the individuals show symptoms or not; public health guidelines required to screen staff every 2-4 weeks depending on the population size where the LTCFs is located	
White et al. ¹⁸ (USA) Peer-Reviewed	Long Term Care/National	Residents tested with RT-PCR or antigen every 3-7 days when there was a confirmed cases in the facility, and tested if they were symptomatic or potential exposure	Post partial/full vaccination cases were monitored using electronic health record data from Genesis Health- Care, a large long-term care provider in the United States (280 nursing homes in 21 States).
Domi et al. ¹⁷ (USA)	Long Term Care/National	In accordance with CMS (Centers for Medicare and Medicaid services) regulations, nursing homes in the same	In this retrospective study, cases were assessed approximately two months into vaccination. The level of vaccination at these facilities was unclear.
Peer-Reviewed		county were required to test all their staff and residents at the same frequency based on the county COVID-19 rate	CMS required all nursing homes to test residents and staff at the same frequency dictated by the rate of COVID-19 in the community not in the facility.
Shrotri et al. ¹⁹ (England) Preprint	Long Term Care/National	LTCF residents underwent monthly routine RT-PCR testing, and if an LTCF outbreak was suspected, local public health teams organised PCR testing for all residents upon notification and 7 days later. Individuals who tested positive were not re-tested for the following 90 days unless they developed new COVID-19 symptoms	This prospective study analyzed cases of COVID-19 during the first three months of vaccine toll-out in the UK. A benefit of this study was access to high- quality routine data for a large, well-defined cohort of LTCF residents who were tested regularly for SARS- CoV-2 throughout follow-up. Also, cohort included a range of LTCF types making findings to be generalisable across LTCF resident population.
Cavanaugh et al. ²² (USA) Peer-Reviewed	Long Term Care/Single facility	Twice-weekly RT-PCR testing of all HCP. Once the outbreak was confirmed, daily rapid point-of-care antigen testing of all residents, regardless of symptoms, was added to the twice-weekly PCR	This was an outbreak investigation report, which described the pre-outbreak surveillance practices and an enhanced active surveillance after the outbreak. 90% and 53% of staff and residents had been fully vaccinated before the outbreak. During







Author (Country)	Setting/Scope	Surveillance method	Highlights from Surveillance
		testing. Additional specimens were collected the same day for RT-PCR confirmation of positive antigen test results. One week after the outbreak was identified, resident antigen testing was reduced to three times weekly, then to twice weekly after no additional cases were identified for 1 week.	the outbreak, 46 COVID-19 cases were identified, including cases in 26 residents (18 fully vaccinated) and 20 HCP (four vaccinated).
Teran et al ²³ (USA) Peer-Reviewed	Long Term Care/City	Monitor infections using a data triangulation method that matches the SARS-CoV-2 test results from RT-PCR and antigen tests reported to the Illinois' National Electronic Disease Surveillance	The Chicago Department of Public Health (CDPH)began matching records to Illinois' Comprehensive Automated Immunization Registry Exchange to identify breakthrough infections. After identifying SARS-CoV-2 infection in a resident 16
		System with facility-reported line lists of SARS-CoV-2 test results from routine screening testing.	days after receipt of a second vaccine dose, CDPH initiated an investigation to quantify breakthrough infections across all facilities. Confirming whether patients with a breakthrough infection and a previous positive SARS-CoV-2 test result had a true reinfection or represented persons with prolonged shedding from previous infection was not possible. Breakthrough infections might be underestimated because of data entry errors or delayed surveillance reporting.
Haas et al ²⁵ (Israel)	Community/National	Voluntary RT-PCR testing based on travel history, symptoms and hospitalization.	A prospective cohort design was implemented using the Israeli national surveillance data from the first 4 months of the nationwide vaccination campaign.
Peer-Reviewed			Only data from fully vaccinated was analyzed. Daily reporting from laboratories to the national database was legally required.
Riley et al. ²⁴ (England)	Community/National	Collected a self-administered throat and nose swab sample and questionnaire data from a random sample of the	This was the 11 th iteration of a surveillance study which was conducted about 5 months into England's vaccination program (April 15 to May 3, 2021).
Preprint		population in England at ages 5 years	Prevalence of new cases were compared with the







Author (Country)	Setting/Scope	Surveillance method	Highlights from Surveillance
		and above. Used the National Health Service (NHS) register of patients to select the sample aiming to obtain similar numbers of participants in each of the 315 lower tier local authorities (LTLAs) in England.B.1.1.7, B.1.617.2	preceding iteration. The authors observed a decline in response rate compared with preceding rounds and there were concerns regarding the representativeness of the samples collected. Based on sequence data for positive samples for which a lineage could be identified, estimated that that 92.3% of infections were from the B.1.1.7 lineage and 7.7% from the B.1.617.2 lineage
Munitz et al. ²⁶ (Israel) Peer-Reviewed	Community and Long- Term Care/National	Approximately 300,000 individual tests collected from Israeli nursing houses and from random "Drive and Check" SARSCoV-2 test complexes.	Monitored the dynamics of the spread of the B.1.1.7 SARS-CoV-2 variant in Israel, using samples collected two months into the vaccine roll-out. The study demonstrated that the B.1.1.7 variant was 45% more transmissible than the wild-type strain in Israel.
Genomic Surve	llance		
Thompson et al. ²⁷ (USA) Peer-Reviewed	Community/City	All RT-PCR positive SARS-CoV-2 specimens, from 9 COVID express laboratories serving New York City, with a cycle threshold (Ct) value <32 underwent whole genome sequencing.	Sequencing was done for samples collected during the first four months of vaccination. The number of persons with reinfection or breakthrough infection whose specimens underwent whole genome sequencing was low, limiting the statistical power to detect modest increases in immune escape that could have a substantial impact on public health. Improved capacity for genomic surveillance, establishment of automated and efficient exchange of WGS data, and integration with population-based clinical and epidemiologic data would enable the rapid characterization of emerging SARS-CoV-2 variants.
Rego et al. ²⁸ (Uruguay)	Community/National	Daily sampling of four diagnostic laboratories was included in the network, that were able to process all	Showed that VOC P.1 was introduced in Uruguay at multiple times over a period of increasing mobility.







Author (Country)	Setting/Scope	Surveillance method	Highlights from Surveillance
Preprint		together more than 3,000 nasopharyngeal samples per day. Of those, between 200 – 300 SARS-CoV2 positive samples were received weekly for qPCR-VOC analysis and 50% of them were further processed for SARS- CoV-2 genome sequencing. Positive RNA samples were obtained from hospitalised cases and outpatient cases collected from all over the country. P1 variants	Samples were collected within the first 3 months of vaccine availability.
Wang et al. ²⁹ (USA) Peer-Reviewed	Community/City	Upper respiratory swab specimens collected from patients as part of routine clinical care. Samples testing positive for SARS-CoV-2 with RT-qPCR Ct \leq 30 or transcription-mediated amplification relative light units (RLU) \geq 1,100 during this period were subject to multiplex allele-specific genotyping.	Specimen were collected during the first three months of vaccine availability in the USA. The assay revealed rapid emergence of L452R in population, with a prevalence of 24.8% in December 2020 that increased to 62.5% in March 2021. This approach can be adapted for emerging mutations and implemented in laboratories already conducting SARS-CoV-2 NAAT using existing resources and extracted nucleic acid
Wastewater Sur	rveillance		
Peterson et al. ³⁴ (Canada) Preprint	Community/Regional	A 24-hr composite wastewater sample was collected three times per week. Wastewater was collected from fifteen urban (Vancouver, Edmonton, Toronto, Montreal and Halifax) wastewater treatment plants (WWTP). Wastewater was also collected from 7 lift stations from remote communities in the Northwest Territories that are not part of the CWS.	Variants of concern were not detected in the Territorial communities, suggesting the absence of variants of concern SARS-CoV-2 cases in those communities. Percentage of variant remained low throughout the study period in the majority of the sites tested. However, the Toronto sites showed a marked increase from ~25% to ~75% over the study period.







Author (Country)	Setting/Scope	Surveillance method	Highlights from Surveillance
Sanjuan et al. ³¹ (Spain) Preprint	Community/City	Wastewaters from the Pinedo and Quart-Benàger Wastewater Treatment plant in the metropolitan area of Valencia (Spain) were sampled (200 mL) by grabbing or taking 4 h composite samples between 7 and 11 am. Sampling was carried out on 129 different days spanning from April 16, 2020, to March 9, 2021.	Time series were similar for wastewaters data and declared cases, but wastewater RNA concentrations exhibited transient peaks that were not observed in declared cases and preceded major outbreaks by several weeks. B.1.1.7 identified.
Fitzgerald et al. ³⁵ (UK) Peer-Reviewed	Community/National	Sites were sampled once a week for RT- PCR testing	There were significant differences between wastewater treatment plants in their capacity to predict case numbers based on influent viral RNA load, with the limit of detection ranging from twenty- five cases for larger plants to a single case in smaller plants.
Fuqua et al. ³³ (USA) Preprint	Community/Regional	RNA isolated from wastewater samples was used to quantify SARS-CoV-2 and analyze the genetic variation through high-throughput sequencing. Bioinformatics approaches were used to rapidly identify single nucleotide genetic alterations, which were compared with known variants of interest and concern.	Differences in the scale of sample pooling in the community revealed unanticipated inconsistencies in variant representation. Variants observed in smaller catchment areas, such as neighbourhood manhole locations, were not observed in downstream treatment plants, suggesting catchment size or population could impact the ability to detect diversity.
Kantor et al. ³² (USA) Preprint	Community/City	RT-PCR testing once a week	The cost for laboratory buildout was approximately \$100,000 USD in capital equipment and took 3 months to complete. The laboratory used the kit-free sewage, salt, silica, and SARS-CoV-2 (4S) direct RNA extraction method and reverse transcription quantitative polymerase chain reaction (RT-qPCR) with a per-sample cost (consumables and reagents) of around \$25 USD.







Author (Country)	Setting/Scope	Surveillance method	Highlights from Surveillance
			Turnaround time (number of days between sample collection and results was 1.6 days
Carcereny et al ³⁰ (Spain)	Community/National	Weekly RT-PCR assay and S gene sequencing with Single nucleotide polymorphism (SNP) identification.	Wastewater-based tracking showed good correlation with clinical data providing information at local level. Study highlighted applicability of Rt-PCR based strategy to track specific mutations of VOC as soon
Peer-Reviewed			as they are identified by clinical sequencing. The relative proportion of B.1.1.7 variant in wastewater could be estimated for 91% of positive samples
Testing air filter	s on public buses		
Hoffman et al. ³⁶ (USA) Preprint	Community/Regional	Individual buses were selected to be sampled via a convenience sampling approach based on which buses could be made available at the depot on a regular basis between 7:00-9:00 AM for sample retrieval. Retrieved filters in the existing HVAC system were sampled. Sample extraction for RT-PCR testing was performed within the same day of the sample collection from metro buses.	SARS-CoV-2 RNA was detected in 14% of public bus filters tested. There was an overlap between pre-and post-vaccination testing periods in this study. Mask mandates were in effect for riders during the sample period, likely reducing the number of viral particles from infected riders landing on the filters.
Metagenomics			
Quinonez et al ³⁷ Peer-Reviewed	NextStrain.org/Internationa	Computational modelling of genomic sequences.	Predicted that the rate of B.1.1.7 lineage is going to sharply decrease (near to zero) in coming months. In contrast, the frequency of other variants, B.1.351, B.1.617, and P.1 will gradually increase. The
			authors suggested a cautious generalizability because of the lack of validation in an experimental study.

Abbreviations: HCW: Healthcare Worker, VOC: Variant of Concern, RT-PCR: Reverse Transcriptase Polymerase Chain Reaction



Table 3: Emerging Technologies

Author (Month, Year)	Type of Technology	Description	Efficacy			
Emerging Tech	Emerging Technology					
Hoffman et al ³⁶ (June, 2021)*§	Air filter detection of SARS-CoV-2 via buses	Novel detection using air filters on 15 buses to test for the presence of trapped SARS- CoV-2 RNA between August 2020 to March 2021 in Seattle.	Presence of SARS-CoV-2 RNA was detected in 24% (20/82) samples of public bus filters.			
Reeves et al. ⁴⁰ (May 2021)	Composite autosampler of wastewater	Withdraws samples from wastewater outfall within surface-accessible manholes. It can be used to monitor and detect SARS-CoV-2 in individual buildings/small groups of buildings.	The composite sampler generally performed well; the design achieved the objectives and provided an economical sampling unit.			
Saha et al. ³⁹ (April, 2021)	Deep learning- based model to detect COVID-19 infection via CT scans and chest x- rays (GraphCovidNet)	A deep learning model (also known as artificial intelligence or machine-learning) that can map CT images and chest x-rays and screen for COVID-19.	The model showed an accuracy of 99% for all datasets analyzed.			
Wendel et al. ³⁸ Wearable tech (2021) (BioButton)		A wearable device that continuously monitors skin temperature, heart rate, and respiratory rate. It can be used for early detection of COVID-19 symptoms.				
Emerging Labo	oratory Testing Techn	ology				
Narasimhan et al ⁴² (April, 2021)§	Serological assay to identify IgM and IgG spike protein in infected and vaccinated individuals	Used the Abbott Alinity serological assays (IgMSP and IgGSP) in combination with Abbott Alinity IgG nucleocapsid antibody test (IgGNC). The serological assay has some utility in evaluating and in distinguishing between infection and vaccination.	100% specific for detecting SARS- CoV-2 naïve individuals. IgMSP/ IgGSp were 96% and 98% sensitive for detecting inpatients with SARS-CoV-2 infection. Vaccination resulted in an increase in IgGSP/IgMSP values, with a rise in IgGSP following the second dose in the naïve group. SARS-CoV-2 infection-recovered			



Author (Month, Year)	Type of Technology	Description	Efficacy
			individuals had several-fold higher IgGSP responses than naïve.
Stromer et al. ⁴³ (Dec 2020)	rapid detection of COVID-19 antigen (NADAL COVID-19 Ag Test) SARS-CoV-2 viral load and identify infectious individuals in a timely manner.		The point-of-care test reliably detected SARS-CoV-2 loads and rapidly identified infectious individuals. Additionally, the test can be useful to help identify patients who no longer transmit the virus.
Suhandynata ⁴⁴ (March, 2021)§	Serological assay to detect previous COVID infection or vaccination	Use of the serological assay Roche S-(spike) antibody and Diazyme neutralizing antibodies (NAbs) assay to detect between SARS-CoV-2 infected and vaccinated individuals.	A combination of S-antibody and N-antibody assays can be used to differentiate naturally infected individuals from vaccinated individuals, as naturally infected individuals are positive on both the S and N-antibody assays.
Trick et al. ⁴⁵ (May 2021)§	Magnetofluidic cartridge platform	Magnetofluidic cartridge platform for automated PCR testing in <30 min. The cartridges were designed for multiplex detection of SARS- CoV-2 with either distinctive variant mutations or with Influenza A and B.	The platform had a limit of detection of 2 copies/µL SARS- CoV-2 RNA with successful identification of B.1.1.7 and B.1.351 variants. Testing with nasopharyngeal swab eluates showed high sensitivity/specificity of SARS-CoV-2, Influenza A and influenza B. Further testing with saliva demonstrated successful detection of all SARS-CoV-2 positive samples with no false positives.
Wang et al ⁴⁶ (May, 2021)*	PCR screening with new assay design for VOI/VOC (multiplex allele specific RT-qPCR)	A genotyping RT-qPCR to conduct high-throughput SARS- CoV-2 variant screening as an alternative to whole-genome sequencing.	The assay had 100% concordance with whole-genome sequencing in a validation subset of 229 specimens, and was able to detect B.1.1.7, B.1.351, B.1.427, B.1.429, B.1.526, and P.2 variants (among others).

Studies marked with an asterix (*) were included in the review of scientific evidence; more information on their findings can be found in Table 2.

§ Indicates preprint.

Abbreviations: RT-PCR: reverse transcriptase polymerase chain reaction; VOC: variants of concern; VOI: variants of interest



Discussion

This review suggests that population surveillance with PCR and or rapid antigen tests were the most commonly used surveillance methods. Other approaches include: genomic surveillance, wastewater surveillance, metagenomics, and sampling of filters on public transport.

The RT-PCR detects the RNA genome of SARS-CoV-2 and has been the mainstay of COVID-19 diagnosis.⁴⁷ As observed in several studies in this review, rapid antigen testing was often used complementarily with RT-PCR and rarely alone as a surveillance tool. This test detects the presence of viral proteins,⁴⁷ is easy to perform, and can be interpreted without specialized training or equipment, thus can be widely distributed with a rapid turnaround time between sampling and results. Rapid antigen tests have generally relatively lower sensitivities compared with RT-PCR.⁴⁷⁻⁴⁹ Consequently, the European Centres for Disease Control (ECDC) suggested a more nuanced approach to rapid antigen testing, suggesting that in a high prevalence setting, a positive result from an antigen test is likely to indicate a true infection and may not require confirmation by RT-PCR;⁵⁰ while any negative test result should be confirmed by RT-PCR immediately.⁵⁰ Conversely, the ECDC suggests that in a low prevalence setting, rapid antigen tests should be able to rule out a highly infectious case; as such, a negative test result may not require confirmation by RT-PCR, whereas a positive test will need immediate sampling for a confirmation by RT-PCR.⁵⁰

Population-level tracking of the origin, distribution, and trends of Covid-19 is challenging, especially considering the rapidly evolving profile of the virus. Wastewater surveillance may provide a non-invasive, anonymous and scalable method of tracking the virus within the population, within a geographic area, at a point in time.⁵¹ However, challenges such as inconsistencies in variant representation,³³ differences in the capacity of wastewater to predict cases³⁵ and build-out cost³² were identified in this review.

A limitation of this review is the lack of details on the methodological approaches to COVID-19 surveillance in the included studies. The majority of the studies were designed as epidemiological studies of existing surveillance programs, therefore, the authors focused on the prespecified study outcomes rather than the practicality of the surveillance programs. Although all the studies included vaccinated populations, there were variations in the reporting of vaccination rate. While some small hospital-based and LTCF studies reported institutional vaccination rates, several large studies did not.



Section 2: International Guidance on Surveillance Methods in a Vaccinated Population

Methods

Due to the anticipation that the primary evidence would stem from websites of international government organizations, a database search was not conducted. A grey literature search was conducted, including a thorough search of Google, websites of international government organizations (e.g., Center for Disease Control and Prevention [CDC], World Health Organization [WHO]), and McMaster Health Forum (COVID-END). This search was primarily examining surveillance guidance published since December 2020 (to capture guidance specific to vaccinations); however, it was expanded to include guidance on surveillance programs that would have been established prior to December 2020 but were still in place. There were no language limitations.

A screening form based on the eligibility criteria was prepared. Citations identified as potentially relevant from the literature search were screened by single reviewer across a team of four reviewers and subsequently read in full text by two reviewers and assessed for eligibility based on the criteria outlined below (Table 4). Discrepancies were resolved by discussion or by a third reviewer. Reference lists of included studies were hand searched to ensure all relevant literature is captured.

Table 4: Criteria for Inclusion of International Guidance on Surveillance

Population	Persons who have been partially or fully vaccinated against COVID-19; populations in settings with a high vaccination rate/low prevalence rate of COVID-19 and low vaccination rate/low prevalence rate of COVID-19 were also considered
Intervention	Surveillance approaches to monitor for resurgence of COVID-19 and variants of concern (e.g., wastewater surveillance and metagenomics, population screening with rapid antigen testing)
Outcome	Any
Guideline Body	Guidance issued by international health organizations
Publication Year	Limited to publication date December 2020-onwards; ongoing surveillance programs established before December 2020 were considered for inclusion

A standardized data extraction sheet was used to extract the month and year of publication, country, scope (e.g., national), surveillance method, vaccination status, population, setting, intended outcomes (e.g., variant surveillance), platform used for surveillance (e.g., any database), guidance summary, and implementation considerations. All reviewers completed a calibration exercise whereby data from two sample studies were extracted by all four reviewers and areas of disagreement were discussed. Data were extracted by one reviewer.



A high-level summary of the guidance pertaining to surveillance across different countries is presented below, followed by a brief discussion of the evidence included in this review; given the rapid nature of this request, a formal risk of bias assessment was not conducted. A patient partner was engaged during the co-production of a plain language summary, which is presented in a separate document.

Results

Through hand searching of grey literature, 68 guidance documents were captured and screened for eligibility. After full-text review, a total of 42 guideline documents were excluded. The most common reason for exclusion was publication date prior to December 2020, without clear indication the surveillance methods were ongoing (n=18). Other reasons for exclusion were: not a guidance document (n=15), not surveillance method(s) (n=6), or duplicate (n=3). A total of 26 guidance documents were included in the synthesis (Table 5); see Table 6 in Appendix B for a summary of the guidance provided across included documents. Most were not specific to vaccinated populations but reported on a surveillance method of COVID-19 and were therefore included in the review; it was assumed that they were still in effect but have not yet updated.



Ď

Table 5: Summary of International Guidance, by Date of Publication

Country	Institute/Author	Scope, Setting, Evidence	Surveillance Method Used
			June 2021
Australia (Southern)	Government of South Australia -	Scope: Regional	Wastewater surveillance
	SA Health ⁵²	Setting: Community	Stated reason for use: Testing wastewater can help provide an early warning signal of COVID-19 infections in people living in a particular
		Level of Evidence: Unclear	wastewater catchment area.
Australia (Western)	Government of Western Australia -	Scope: Regional	Wastewater surveillance
	Department of Health ⁵³	Setting: Community Level of Evidence: Unclear	Stated reason for use: Wastewater testing will complement – but cannot replace – other kinds of COVID-19 testing, including nose and throat swabs. Wastewater testing indicates if COVID-19 may be present in the broader
			community.
Germany	Federal Ministry of Health ⁵⁴	Scope: National	Digital support for health authorities, digital symptom diary, contact management
		Setting: Community	
		Level of Evidence: Unclear	Stated reason for use: Enable nationwide, secure and fast electronic reporting and information processing with regard to positive SARS-CoV2. In this way, the effort for the reporting laboratories and the responsible health authorities and state authorities is to be reduced, and infection events that occur are to be contained by the possibility of introducing targeted infection protection measures more quickly.
			May 2021
UK	Public Health England ⁵⁵	Scope: National	Serosurveillance, population PCR
		Setting: School, healthcare setting, community	Stated reason for use: Children represent a small proportion of the total number of confirmed COVID-19 cases. There are limited data on childhood SARS-CoV-19infections, especially from Europe. Public Health England
		Level of Evidence: Evidence informed	(PHE) along with NHS partners and academic collaborators has implemented a number of ongoing surveillance programmes to monitor the course, progression and outcomes of COVID-19 in children.







USA	CDC ⁵⁶	Scope: National	Population genomic screening
		Setting: Community	Stated reason for use: Improve our understanding of which variants are circulating the US, how quickly variants emerge, and which variants are the
		Level of Evidence: Evidence	most important to characterize and track in the terms of health.
			April 2021
Australia	Communicable	Scope: National	Case-based reporting, surveillance of outbreaks and clusters, targeted
	Diseases Network Australia ⁵⁷	Setting: Community	active case finding, syndromic and sentinel surveillance, serosurveillance, virus genomics, monitoring of personal behaviours
		Level of Evidence: Evidence informed	State reason for use: Australia continues to follow a suppression strategy in response to COVID-19. Each disease surveillance goal contributes information, via key indicators, that support strategic and operational decision-making by national and jurisdictional governments and public health authorities.
France	Sante Publique France ⁵⁸	Scope: National, outside of Brittany	Population PCR screening, with sequencing of SA variant cases
		Setting: Community Level of Evidence: Unclear	Stated reason for use: to describe probable and confirmed cases linked to the B.1.616 variant and to monitor the geographical expansion of this variant outside of Brittany to adapt appropriate measures.
India	Ministry of Health and Family	Scope: National	Population genomic screening
	Welfare, Government of India ⁵⁹	Setting: Community Level of Evidence: Unclear	Stated reason for use: Gather whole genome sequencing information in the community by targeting events like clustering of COVID cases, suspected super-spreader events, clustering of cases in institutions, suspected vaccine failure and re-infection clusters etc.
International	Pan American Health Association/WHO ⁶⁰	Scope: International Setting: Community	Population PCR screening for both influenza and COVID-19, population genomic screening







USA	CDC ⁶¹	Level of Evidence: Evidence informed Scope: National Setting: Community Level of Evidence: Unclear	 Stated reason for use: The threat of influenza epidemics and pandemics persists. It is imperative for the WHO's Global Influenza Surveillance and Response System to maintain meaningful surveillance of influenza worldwide and for countries to remain vigilant while adapting to meet COVID-19 surveillance objectives. Population genomic screening Stated reason for use: National and global sequencing efforts have identified changes in the SARS-CoV-2 genetic code resulting from transmission and evolution in humans and animals. These changes can affect many aspects of our response including transmission, diagnostics, thereaution and upgenetics.
			therapeutics, and vaccines. March 2021
France	Sante Publique	Scope: National	Population PCR screening, with sequencing of SA variant cases
	France ⁶²	Setting: Healthcare Level of Evidence: Unclear	Stated reason for use : To track the epidemiologic characteristics of severe influenza and COVID-19 cases admitted to the ICU; to document the specific contribution of influenza and SARS-CoV-2 viruses among ICU admissions; and to describe and document the comorbidities and characteristics of patients admitted to the ICU for influenza or SARS-CoV-2 infection.
UK	Public Health England ⁶³	Scope: National Setting: Community, health care setting, long-term care Level of Evidence: Evidence informed	PCR screening, serosurveillance, hospital screening, genome sequencing Stated reason for use: To monitor coverage of the vaccine in targeted populations and identify under vaccinated groups; to rapidly detect and evaluate possible adverse events associated with vaccination; to estimate the effectiveness of the vaccine at preventing a spectrum of disease outcomes and onwards transmission in different targeted populations, and against different viral variants, as well as the duration of any protective effect; to identify risk factors for and outcomes of vaccine failure, including any impact on strain evolution; to monitor the overall impact of the vaccination programme on COVID-19 in the wider population including the indirect effect on groups not targeted by the vaccination programme; to







			monitor the impact of the vaccination programme on prevalence of antibodies against COVID-19 as an indicator of population level immunity, and to monitor antibody waning in the population; to monitor attitudes to vaccination and identify barriers to high vaccine uptake, and; to monitor inequalities in each of these outcome measures
		Fe	ebruary 2021
International	Pan American Health	Scope: International	Population genomic screening
	Association/WHO ⁶⁴	Setting: Community	Stated reason for use: A time series of samples is necessary to detect trends of change in genetic diversity and emerging variants. As well,
		Level of Evidence: Evidence informed	appropriate number and representative samples, including unusual case samples, are important for generating reliable genomic sequencing data.
Spain	Ministry of Health – Spain ⁶⁵	Scope: National	PCR screening, rapid antigen screening, genomic screening
		Setting: Community, health care settings, long term care, prisons Level of Evidence: Evidence	Stated reason for use: Early detection of cases with active SARS-CoV-2 infection; the early establishment of necessary control measures to prevent new infections; the availability of the necessary information for epidemiological surveillance, with a level of adequate disaggregation and detail.
		informed	
USA	CDC ⁶⁶	Scope: National	Serosurveillance
		Setting: Community	Stated reason for use: To better understanding how many infections with SARS-CoV-2 have occurred at different time points, in different locations,
		Level of Evidence: Evidence informed	and within different populations in the US.
January 2021			







Europe	ECDC ⁶⁷	Scope: International	Genomic surveillance (Pre-screening RT-PCR before testing for emerging variants)
		Setting: Community	
			Stated reason for use: To detect introduction of known variants and
		Level of Evidence: Evidence	control the spread and impact of emerging variants.
		informed	
France	Sante Publique France ⁶⁸	Scope: National	Population PCR screening, with sequencing of UK and SA variant cases
		Setting: Community, points	Stated reason for use: To document the circulation of the UK variant and
		of entry for travel	the South African variant in France and slow their spread.
		Level of Evidence: Unclear	
Spain	Ministry of Health – Spain ⁶⁹	Scope: National	Population genomic screening
	•	Setting: Community	Stated reason for use: Determine the incidence of variants of interest for public health; early identification of new variants that present increased
		Level of Evidence: Evidence	transmissibility/virulence, vaccine breakthrough, or phenotypic change;
		informed	identification of vulnerable groups associated with new variants; carry out viral phylodynamic studies.
		De	cember 2020
International	WHO ⁷⁰	Scope: International	Nucleic acid amplification tests, antigen-detecting rapid diagnostic tests, Antibody detection (serology), reporting/epidemiological data
		Setting: Community, health	
		care settings, sentinel sites,	Stated reason for use: The aim of national surveillance for COVID-19 is to
		closed settings, travelers at	enable public health authorities to reduce transmission of SARS-CoV-2,
		points of entry	thereby limiting associated morbidity and mortality. The objectives of
		Level of Evidence, Evidence	COVID-19 surveillance are to: Enable rapid detection, isolation, testing, and
		Level of Evidence: Evidence informed	management of cases; detect and contain clusters and outbreaks,
			especially among vulnerable populations; identify, follow-up and quarantine contacts; guide the implementation and adjustment of targeted control
			measures, while enabling safe resumption of economic and social activities;
			evaluate the impact of the pandemic on health care systems and society;
			monitor longer term epidemiologic trends and evolution of SARS-CoV-2







		virus and monitor trends in covid-19 deaths, and; contribute to the understanding of the co-circulation of SARS-CoV-2 virus, influenza and other respiratory viruses, and other pathogens.		
		Να	ovember 2020	
Europe	ECDC ⁷¹	Scope: International	Population rapid antigen screening	
		Setting: Community, healthcare setting	Stated reason for use: Rapid antigen tests can offer a significant advantage over RT-PCR in terms of bringing testing closer to persons to test and timeliness of results. Benefits of rapid antigen testing include:	
		Level of Evidence: Evidence informed	prompt clinical management of cases with COVID-19-compatible symptoms at admission; control transmission – early detection of cases, contact tracing, population-wide testing; mitigate the impact of COVID-19 in	
			healthcare and social-care settings: triage at admission, early detection and isolation; identify clusters or outbreaks in specific settings: early detection and isolation.	
UK	Wade et al. Summary for	Scope: National	Wastewater surveillance	
	SAGE ⁷²	Setting: Community	Stated reason for use: Wastewater surveillance is a reliable, timely and cost-effective method to serve the needs of public health.	
		Level of Evidence: Evidence informed		
USA	CDC ^{73,74}	Scope: National	Wastewater surveillance	
		Setting: Community	Stated reason for use: To complement other COVID-19 surveillance indicators that inform public health actions.	
		Level of Evidence: Evidence informed		
		A	August 2020	
Brazil	Ministry of Health Brazile (Ministerio	Scope: National	Case-based reporting and laboratory reporting of positive cases; Sentinel surveillance via Influenza sentinel surveillance network	
	de Saude) 75	Setting: Community	Stated reason for use: Early identification of the occurrence of COVID-19	
		Level of Evidence: Unclear	cases; establish criteria for the notification and registration of suspected	







			cases in health services, public and private; establish procedures for laboratory investigation; monitor and describe the pattern of morbidity and mortality from COVID-19; monitor the clinical and epidemiological characteristics of the SARS-CoV-2 virus; establish prevention and control measures, and; carry out timely and transparent communication of the epidemiological situation in Brazil
USA	CDC ⁷⁶	Scope: National	Hospitalization secondary to COVID-19
		Setting: Community Level of Evidence: Evidence informed Stated reason for use: Coronavirus Disease 2019 Associated Hospitalization Surveillance Network (COVID-NET) is a population-bas surveillance system that collects data on laboratory-confirmed COVID- associated hospitalizations among children and adults through a netwo over 250 acute-care hospitals in 14 states. COVID-NET is CDC's sour important data and provides important clinical information on COVID-1 associated hospitalizations, including age group, sex, race/ethnicity ar underlying health conditions.	
			April 2020
Europe	ECDC ⁷⁷	Scope: International	Symptoms and population PCR screening
		Setting: Community, healthcare settings, long- term care Level of Evidence: Evidence informed	Stated reason for use: Monitor the intensity, geographic spread and severity of COVID-19 in the population in order to estimate the burden of disease, assess the direction of recent time trends, and inform appropriate mitigation measures; monitor viral changes to inform drug and vaccine development, and to identify markers of severe infection; monitor changes in which risk groups are most affected in order to better target prevention efforts; monitor the epidemic's impact on the healthcare system to predict the trajectory of the epidemic curve and inform resource allocation and mobilization of surge capacity as well as external emergency support; monitor the impact of any mitigation measures to inform authorities so they can adjust the choice of measures, as well as their timing and intensity; detect and contain nosocomial outbreaks to protect healthcare workers and patients, and; detect and contain outbreaks in long-term care facilities and







			other closed communities to protect those most at risk of severe disease and poor outcomes.
		Dat	e not reported
New Zealand	Ministry of Health	Scope: National	Wastewater surveillance
		Setting: Community	Stated reason for use: Wastewater testing is being used as an extra tool to help monitor for COVID-19. Wastewater testing may be able to give us
		Level of Evidence: Unclear	an early warning of COVID-19 cases in the community. This will help to alert local communities to be more vigilant, keep up hygiene measures, and get tested and stay home if they are unwell.



Guidance documents from 11 countries/regions were identified including Australia,^{52,53,57} Brazil,⁷⁵ Europe,^{67,71,77} France,^{58,62,68} Germany,⁵⁴ India,⁵⁹ International,^{60,64,70} New Zealand,⁷⁸ Spain,^{65,69} the United Kingdom^{55,63,72} and the United States.^{56,61,66,73,74,76} Documents were derived from government websites (Departments/Ministries of Health, National Governments), subsidiaries of national governments (e.g., Public Health England, Centre for Disease Control), or from international organizations (e.g., World Health Organization, Pan American Health Association, and European Centre for Disease Control). The scope of the guidance documents was mostly national-focused (n=17), however there were some that were international- (n=6) and regional-focused (n=3).

All of the guidance documents included surveillance methods conducive for community settings. Other settings of interest were healthcare setting including hospitals and primary care centres, ^{55,63,65,68,70} long-term care facilities, ^{63,65} points of entry for travel, ^{68,70} schools, ⁵⁵ and other sentinel sites (e.g., prisons and closed settings). ^{65,70}

Seven overarching surveillance methods emerged in the literature. PCR-testing was the most recommended surveillance method (n=11), followed by genomic screening (n=9), serosurveillance (n=5), wastewater surveillance (n=5), antigen testing (n=3), health record screening (n=2), and syndromic surveillance (n=2) (Figure 3).




Figure 3: Surveillance Methods Reported in Included International Guidelines (n=26)



Vaccine-Specific Surveillance

Only one document was specific to surveillance methods to be deployed in a vaccinated population. The Public Health England *COVID-19 Vaccine Surveillance Strategy*⁶³ recommends surveillance methods including PCR-testing, health record screening, serosurveillance, and genome sequencing with the following objectives:

- To monitor coverage of the vaccine in targeted populations and identify under-vaccinated groups;
- to rapidly detect and evaluate possible adverse events associated with vaccination;
- to estimate the effectiveness of the vaccine at preventing a spectrum of disease outcomes and onwards transmission in different targeted populations, and against different viral variants, as well as the duration of any protective effect;
- to identify risk factors for and outcomes of vaccine failure, including any impact on strain evolution;
- to monitor the overall impact of the vaccination program on COVID-19 in the wider population including the indirect effect on groups not targeted by the vaccination program;
- to monitor the impact of the vaccination program on prevalence of antibodies against COVID-19 as an indicator of population level immunity, and to monitor antibody waning in the population;
- to monitor attitudes to vaccination and identify barriers to high vaccine uptake, and;
- to monitor inequalities in each of these outcome measures.

Discussion

Comprehensive hand-searching for international guidance on surveillance methods of COVID-19 yielded 26 documents. Most were not specific to vaccinated populations but reported on a surveillance method of COVID-19 and were therefore included in the review; it was assumed that they were still in effect but have not yet been updated. Seven surveillance methods emerged from the guidance documents: PCR-testing, genomic screening, serosurveillance, wastewater surveillance, antigen testing, health record screening, and syndromic surveillance. Many of the surveillance methods were recommended for use in community settings, however PCR-testing, antigen testing, genomic screening, serosurveillance, antigen testing, serosurveillance, and health record screening were also recommended for targeted settings such as health care facilities, long-term care facilities, schools, and points of entry for travelers.

The objectives of the surveillance methods were consistent across countries. PCR-testing, antigentesting, syndromic surveillance, health record screening, and serosurveillance should be used to: monitor the intensity, spread, and severity of COVID-19 in order to estimate the burden of disease,



identify at-risk populations, identify outbreaks, to adjust public health measures as needed. Additionally, genomic sequencing should be used to identify variations and evolution of SARS-CoV-2 to identify variants of concern. Wastewater surveillance should be used to complement other surveillance methods, to detect if COVID-19 and its variants are present in a community setting.

Only one document (published by Public Health England) was identified that provided guidance specific to surveillance of vaccinated populations. Public Health England details their plan to surveil and monitor COVID-19 in vaccinated populations in the UK, including conducting cohort studies such as SIREN, VIVALDI, and CONSENSUS studies.⁶³ These will involve routine surveillance, enhanced surveillance, use of electronic health records, surveillance of vaccine failure (including follow-up with viral whole genome sequencing) and sero-surveillance (including blood donor samples, routine blood tests, and residual sera).

There are several limitations to this review. Given the rapid nature of this report and the evidence of interest (i.e., international guidance), we were unable to carry-out an exhaustive systematic search of the literature. Therefore, the international guidance captured here may not include all countries'/institutes' guidance for surveillance. Additionally, we were unable to address the quality of evidence reported in the guidance documents because of the variation in reporting and level of detail in the included documents.

Conclusions

Evidence for post-vaccination COVID-19 surveillance was derived from studies in partially or fully vaccinated populations. Population PCR screening, supplemented by rapid antigen tests, was the most frequently used surveillance method and also the most commonly recommended across jurisdictions. The selection of testing method and the frequency of testing was determined by the intensity of the disease and the scale of testing. Other common testing methods included wastewater surveillance and genomic surveillance. A few novel technologies are emerging, however, many of these are yet to be utilized in the real-world setting. There is limited evidence-based guidance on surveillance in a vaccinated population. Most recent guidance on COVID-19 surveillance is not specific to vaccinated individuals, or it is in effect but has not yet been updated to reflect that. Therefore, more evidence-informed guidance on testing and surveillance approaches in a vaccinated population that incorporates all testing modalities is required.



References

1. Johns Hopkins University. COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). 2021. <u>https://www.covidtracker.com/</u> (accessed 23 June 2021.

2. Xing K, Tu X-Y, Liu M, et al. Efficacy and safety of COVID-19 vaccines: a systematic review. *Zhongguo Dang Dai Er Ke Za Zhi* 2021; **23**(3): 221-8.

3. Our World in Data. Coronavirus (COVID-19) Vaccinations. 2021.

https://ourworldindata.org/covid-vaccinations (accessed June 23 2021).

4. Du Z, Pandey A, Bai Y, et al. Comparative cost-effectiveness of SARS-CoV-2 testing strategies in the USA: a modelling study. *The Lancet Public Health* 2021; **6**(3): e184-e91.

5. McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V, Lefebvre C. PRESS peer review of electronic search strategies: 2015 guideline statement. *Journal of clinical epidemiology* 2016; **75**: 40-6.

6. Jacobson KB, Pinsky BA, Rath MEM, et al. Post-vaccination SARS-CoV-2 infections and incidence of the B.1.427/B.1.429 variant among healthcare personnel at a northern California academic medical center. *medRxiv* 2021.

7. Hall VJ, Foulkes S, Saei A, et al. COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study. *Lancet* 2021; **397**(10286): 1725-35.

8. Sansone E, Tiraboschi M, Sala E, et al. Effectiveness of BNT162b2 vaccine against the B.1.1.7 variant of SARS-CoV-2 among healthcare workers in Brescia, Italy. *J Infect* 2021; **83**(1): e17-e8.

9. Cucunawangsih C, Wijaya RS, Lugito NPH, Suriapranata I. Post-vaccination cases of COVID-19 among healthcare workers at Siloam Teaching Hospital, Indonesia. *Int J Infect Dis* 2021; **107**: 268-70.

10. Bouton TC, Lodi S, Turcinovic J, et al. COVID-19 vaccine impact on rates of SARS-CoV-2 cases and post vaccination strain sequences among healthcare workers at an urban academic medical center: a prospective cohort study. *medRxiv* 2021.

11. Baj A, Novazzi F, Genoni A, et al. Symptomatic SARS-CoV-2 infections after full schedule BNT162b2 vaccination in seropositive healthcare workers: a case series from a single institution. *Emerg Microbes Infect* 2021; **10**(1): 1254-6.

12. Angel Y, Spitzer A, Henig O, et al. Association Between Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections Among Health Care Workers. *Jama* 2021; **325**(24): 2457-65.

13. Tang L, Hijano DR, Gaur AH, et al. Asymptomatic and Symptomatic SARS-CoV-2 Infections After BNT162b2 Vaccination in a Routinely Screened Workforce. *Jama* 2021; **325**(24): 2500-2.

14. Lutrick K, Ellingson KD, Baccam Z, et al. COVID-19 Infection, Reinfection, and Vaccine Effectiveness in a Prospective Cohort of Arizona Frontline/Essential Workers: The AZ HEROES Research Protocol. *JMIR Res Protoc* 2021.

15. Jones NK, Rivett L, Seaman S, et al. Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection. *Elife* 2021; **10**.

16. Tyagi K, Ghosh A, Nair D, et al. Breakthrough COVID19 infections after vaccinations in healthcare and other workers in a chronic care medical facility in New Delhi, India. *Diabetes Metab Syndr* 2021; **15**(3): 1007-8.



17. Domi M, Leitson M, Gifford D, Nicolaou A, Sreenivas K, Bishnoi C. The BNT162b2 vaccine is associated with lower new COVID-19 cases in nursing home residents and staff. *J Am Geriatr Soc* 2021.

 White EM, Yang X, Blackman C, Feifer RA, Gravenstein S, Mor V. Incident SARS-CoV-2 Infection among mRNA-Vaccinated and Unvaccinated Nursing Home Residents. *N Engl J Med* 2021.
 Shrotri M, Krutikov M, Palmer T, et al. Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of Long-Term Care Facilities (VIVALDI study). *medRxiv* 2021: 2021.03.26.21254391.

20. Rudolph JL, Hartronft S, McConeghy K, et al. Proportion of SARS-CoV-2 positive tests and vaccination in Veterans Affairs Community Living Centers. *J Am Geriatr Soc* 2021.

21. De Salazar PM, Link N, Lamarca K, Santillana M. High coverage COVID-19 mRNA vaccination rapidly controls SARS-CoV-2 transmission in Long-Term Care Facilities. *medRxiv* 2021.

22. Cavanaugh AM, Fortier S, Lewis P, et al. COVID-19 Outbreak Associated with a SARS-CoV-2 R.1 Lineage Variant in a Skilled Nursing Facility After Vaccination Program - Kentucky, March 2021. *MMWR Morb Mortal Wkly Rep* 2021; **70**(17): 639-43.

23. Teran RA, Walblay KA, Shane EL, et al. Postvaccination SARS-CoV-2 Infections Among Skilled Nursing Facility Residents and Staff Members - Chicago, Illinois, December 2020-March 2021. *MMWR Morb Mortal Wkly Rep* 2021; **70**(17): 632-8.

24. Riley S, Haw D, Walters CE, et al. REACT-1 round 11 report: low prevalence of SARS-CoV-2 infection in the community prior to the third step of the English roadmap out of lockdown. *medRxiv* 2021: 2021.05.13.21257144.

25. Haas EJ, Angulo FJ, McLaughlin JM, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. *Lancet* 2021; **397**(10287): 1819-29.

26. Munitz A, Yechezkel M, Dickstein Y, Yamin D, Gerlic M. BNT162b2 vaccination effectively prevents the rapid rise of SARS-CoV-2 variant B.1.1.7 in high-risk populations in Israel. *Cell Rep Med* 2021; **2**(5): 100264.

27. Thompson CN, Hughes S, Ngai S, et al. Rapid Emergence and Epidemiologic Characteristics of the SARS-CoV-2 B.1.526 Variant - New York City, New York, January 1-April 5, 2021. *MMWR Morb Mortal Wkly Rep* 2021; **70**(19): 712-6.

28. Rego N, Costábile A, Paz M, et al. Implementation of a qPCR assay coupled with genomic surveillance for real-time monitoring of SARS-CoV-2 variants of concern. *medRxiv* 2021: 2021.05.20.21256969.

29. Wang H, Miller JA, Verghese M, et al. Multiplex SARS-CoV-2 Genotyping RT-PCR for Population-Level Variant Screening and Epidemiologic Surveillance. *J Clin Microbiol* 2021: Jcm0085921.

30. Carcereny A, Martínez-Velázquez A, Bosch A, et al. Monitoring emergence of SARS-CoV-2 B. 1.1. 7 Variant through the Spanish National SARS-CoV-2 Wastewater Surveillance System (VATar COVID-19) from December 2020 to March 2021. *medRxiv* 2021.

31. Sanjuán R, Domingo-Calap P. Reliability of wastewater analysis for monitoring COVID-19 incidence revealed by a long-term follow-up study. *medRxiv* 2021: 2021.05.30.21257992.

32. Kantor RS, Greenwald HD, Kennedy LC, et al. Operationalizing a routine wastewater monitoring laboratory for SARS-CoV-2. *medRxiv* 2021: 2021.06.06.21258431.



33. Fuqua JL, Rouchka EC, Waigel S, et al. A rapid assessment of wastewater for genomic surveillance of SARS-CoV-2 variants at sewershed scale in Louisville, KY. *medRxiv* 2021.

34. Peterson SW, Lidder R, Daigle J, et al. RT-qPCR detection of SARS-CoV-2 mutations S 69-70 del, S N501Y and N D3L associated with variants of concern in Canadian wastewater samples. *medRxiv* 2021: 2021.05.20.21257536.

35. Fitzgerald SF, Rossi G, Low AS, et al. COVID-19 mass testing: harnessing the power of wastewater epidemiology. *medRxiv* 2021: 2021.05.24.21257703.

36. Hoffman J, Hirano M, Panpradist N, et al. Passively Sensing SARS-CoV-2 RNA in Public Transit Buses. *medRxiv* 2021: 2021.06.02.21258184.

37. Quinonez E, Vahed M, Hashemi Shahraki A, Mirsaeidi M. Structural Analysis of the Novel Variants of SARS-CoV-2 and Forecasting in North America. *Viruses* 2021; **13**(5).

38. Wendel SK, Zane, R., Faruki, A. BioButton COVID-19 vaccination monitoring operational pilot. 2021.

39. Saha P, Mukherjee D, Singh PK, Ahmadian A, Ferrara M, Sarkar R. GraphCovidNet: A graph neural network based model for detecting COVID-19 from CT scans and X-rays of chest. *Sci Rep* 2021; **11**(1): 8304.

40. Reeves K, Leibig J, Feula A, et al. High-resolution within-sewer SARS-CoV-2 surveillance facilitates informed intervention. *medRxiv* 2021: 2021.05.24.21257632.

41. Thompson MG, Burgess JL, Naleway AL, et al. Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers - Eight U.S. Locations, December 2020-March 2021. *MMWR Morb Mortal Wkly Rep* 2021; **70**(13): 495-500.

42. Narasimhan M, Mahimainathan L, Araj E, et al. Clinical Evaluation of the Abbott Alinity SARS-CoV-2 Spike-Specific Quantitative IgG and IgM Assays among Infected, Recovered, and Vaccinated Groups. *J Clin Microbiol* 2021; **59**(7): e0038821.

43. Strömer A, Rose R, Schäfer M, et al. Performance of a Point-of-Care Test for the Rapid Detection of SARS-CoV-2 Antigen. *Microorganisms* 2020; **9**(1).

44. Suhandynata RT, Bevins NJ, Tran JT, et al. SARS-CoV-2 Serology Status Detected by Commercialized Platforms Distinguishes Previous Infection and Vaccination Adaptive Immune Responses. *medRxiv* 2021.

45. Trick AY, Chen F-E, Chen L, et al. Magnetofluidic platform for rapid multiplexed screening of SARS-CoV-2 variants and respiratory pathogens. *medRxiv* 2021: 2021.05.10.21256995.

46. Wang H, Miller JA, Verghese M, et al. Multiplex SARS-CoV-2 Genotyping PCR for Population-Level Variant Screening and Epidemiologic Surveillance. *medRxiv* 2021: 2021.04.20.21255480.

47. Mercer TR, Salit M. Testing at scale during the COVID-19 pandemic. *Nature Reviews Genetics* 2021; **22**(7): 415-26.

48. Scohy A, Anantharajah A, Bodéus M, Kabamba-Mukadi B, Verroken A, Rodriguez-Villalobos H. Low performance of rapid antigen detection test as frontline testing for COVID-19 diagnosis. *Journal of Clinical Virology* 2020; **129**: 104455.

49. Perchetti GA, Huang M-L, Mills MG, Jerome KR, Greninger AL. Analytical sensitivity of the Abbott BinaxNOW COVID-19 Ag card. *Journal of Clinical Microbiology* 2020; **59**(3): e02880-20.

50. Control ECfDPa. Options for the use of rapid antigen tests for COVID-19 in the EU/EEA and the UK, 2020.



51. Public Health Ontario. Focus on Wastewater surveillance of COVID-192021. https://www.publichealthontario.ca/-/media/documents/ncov/phm/2021/04/public-health-measureswastewater-surveillance.pdf?la=en (accessed 23 June 2021).

52. Government of South Australia. COVID-19 Wastewater Surveillance Program. 2021. https://www.sahealth.sa.gov.au/wps/wcm/connect/public+content/sa+health+internet/conditions/infectio us+diseases/covid-19/response+and+restrictions/covid-19+wastewater+surveillance+program (accessed June 11 2021).

53. Government of Western Australia Department of Health. COVID-19 wastewater testing. 2021. <u>https://ww2.health.wa.gov.au/Articles/A_E/Coronavirus/COVID19-wastewater-testing</u> (accessed June 11 2021).

54. Federal Ministry of Health - Germany. Digital support for health authorities. 2021. https://www.bundesgesundheitsministerium.de/404/ (accessed June 10 2021).

55. Public Health England. COVID-19: paediatric surveillance. 2021.

https://www.gov.uk/guidance/covid-19-paediatric-surveillance#covid-19-surveillance-in-schools-inengland (accessed June 11 2021).

56. Centers for Disease Control and Prevention. Genomic Surveillance for SARS-CoV-2 Variants. May 17, 2021 2021. <u>https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-surveillance.html</u> (accessed June 9 2021).

57. Communicable Diseases Network Australia. Australian National Disease Surveillance Plan for COVID-19, 2021.

58. Santé publique France. Protocole national d'investigation (hors Bretagne) des infections à SARS-COV-2 liées au variant 20C/H655Y, 2021.

59. Government of India Ministry of Health and Family Welfare. Guidelines for selecting the samples for WGS, 2021.

60. Pan American Health Organization. Guidance for the implementation of the Influenza and SARS-CoV-2 Multiplex RT-PCR Assay into the influenza and COVID-19 integrated surveillance, 2021.
 61. Centers for Disease Control and Prevention. National SARS-CoV-2 Strain Surveillance (NS3)

Submissions to CDC for SARS-CoV-2 Positive Specimens, 2021.

62. Santé publique France. Protocole de la surveillance sentinelle des cas graves de grippe et de COVID-19 nécessitant une prise en charge en réanimation, année 2020-2021, 2021.

63. Public Health England. COVID-19 vaccine surveillance strategy, 2021.

64. Pan American Health Organization. Guidance for SARS-CoV-2 samples selection for genomic characterization and surveillance, 2021.

65. Ministro De Sanidad - Gobierno De Espana. ESTRATEGIA DE DETECCIÓN PRECOZ, VIGILANCIA Y CONTROL DE COVID-19, 2021.

66. Centers for Disease Control and Prevention. COVID-19 Serology Surveillance Strategy. 2021. <u>https://www.cdc.gov/coronavirus/2019-ncov/covid-data/serology-surveillance/index.html</u> (accessed June 10 2021).

67. European Centre for Disease Prevention and Control. Risk related to the spread of new SARS-CoV-2 variants of concern in the EU/EEA - first update, 2021.

68. Sante publique France. Conduite à tenir pour la détection et l'investigation des cas suspects ou confirmés du nouveau variant VOC202012/01 UK et 501.V2 Sud-Africain, 2021.

69. Ministerio de Sanidad - Gobierno de Espana. INTEGRACIÓN DE LA SECUENCIACIÓN GENÓMICA EN LA VIGILANCIA DEL SARS-CoV-2, 2021.

70. World Health Organization. Public health surveillance for COVID-19, 2020.



71. European Centre for Disease Prevention and Control. Options for the use of rapid antigen tests for COVID-19 in the EU/EEA and the UK, 2020.

72. Wade M, Jones, D., Singer, A., Hart, A., Corbishley, A., Spence, C., Morvan, M., Zhang, C., Pollock, M., Hoffmann, T., Singleton, P., Grimsley, J., Bunce, J., Engeli, A., Henderson, G.,. Wastewater COVID-19 Monitoring in the UK: Summary for SAGE – 19/11/20, 2020.

73. Centers for Disease Control and Prevention. Developing a Wastewater Surveillance Sampling Strategy. November 23, 2020 2020. <u>https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/wastewater-surveillance/developing-a-wastewater-surveillance-sampling-strategy.html</u> (accessed June 10 2021).

74. Centers for Disease Control and Prevention. Wastewater Surveillance Testing Methods November 23, 2020 2020. <u>https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/wastewater-surveillance/testing-methods.html</u> (accessed June 10 2021).

75. MINISTÉRIO DA SAÚDE - Brazil. Guia de Vigilância Epidemiológica, 2020.

76. Centers for Disease Control and Prevention. Coronavirus Disease 2019 (COVID-19)-AssociatedHospitalization Surveillance Network (COVID-NET). 2020.

https://www.cdc.gov/coronavirus/2019-ncov/covid-data/covid-net/purpose-methods.html (accessed June 10 2021).

77. European Centre for Disease Prevention and Control. Strategies for the surveillance of COVID-19, 2020.

78. Ministry of Health NZ. COVID-19: Wastewater testing. 2021. <u>https://www.health.govt.nz/our-work/diseases-and-conditions/covid-19-novel-coronavirus/covid-19-health-advice-public/covid-19-wastewater-testing</u> (accessed June 11 2021).



Appendix A: Search Strategies for Scientific Evidence of Surveillance

Ovid Multifile

Database: EBM Reviews - Cochrane Central Register of Controlled Trials <May 2021>, EBM Reviews - Cochrane Database of Systematic Reviews <2005 to June 9, 2021>, Embase <1974 to 2021 June 11>, Ovid MEDLINE(R) and Epub Ahead of Print, In-Process, In-Data-Review & Other Non-Indexed Citations and Daily <1946 to June 11, 2021>

Search Strategy:

- 1 COVID-19/ (85559)
- 2 SARS-CoV-2/ (81242)
- 3 Coronavirus/ (13278)
- 4 Betacoronavirus/ (40986)
- 5 Coronavirus Infections/ (57260)
- 6 (COVID-19 or COVID19).tw,kf. (253916)
- 7 ((coronavirus* or corona virus*) and (hubei or wuhan or beijing or shanghai)).tw,kf. (9779)
- 8 (wuhan adj5 virus*).tw,kf. (519)
- 9 (2019-nCoV or 19nCoV or 2019nCoV).tw,kf. (3166)
- 10 (nCoV or n-CoV or "CoV 2" or CoV2).tw,kf. (92137)

11 (SARS-CoV-2 or SARS-CoV2 or SARSCoV-2 or SARSCoV2 or SARS2 or SARS-2 or severe acute respiratory syndrome coronavirus 2).tw,kf. (93701)

12 (2019-novel CoV or Sars-coronavirus2 or Sars-coronavirus-2 or SARS-like coronavirus* or ((novel or new or nouveau) adj2 (CoV or nCoV or covid or coronavirus* or corona virus or Pandemi*2)) or (coronavirus* and pneumonia)).tw,kf. (35999)

- 13 (novel coronavirus* or novel corona virus* or novel CoV).tw,kf. (18244)
- 14 ((coronavirus* or corona virus*) adj2 "2019").tw,kf. (58052)
- 15 ((coronavirus* or corona virus*) adj2 "19").tw,kf. (9366)
- 16 ("coronavirus 2" or "corona virus 2").tw,kf. (29952)
- 17 (OC43 or NL63 or 229E or HKU1 or HCoV* or Sars-coronavirus*).tw,kf. (7566)
- 18 COVID-19.rx,px,ox. or severe acute respiratory syndrome coronavirus 2.os. (6367)
- 19 (coronavirus* or corona virus*).ti. (43970)



- 20 ("B.1.1.7" or "B.1.351" or "B.1.617" or "B.1.427" or "B.1.429").tw,kf,rx,px,ox. (626)
- 21 ("P.1" and (Brazil* or variant?)).tw,kf,rx,px,ox. (3431)
- 22 ((alpha or beta or delta or gamma) adj3 variant?).tw,kf. (11593)
- 23 or/1-22 [COVID-19] (329554)
- 24 vaccinated.tw,kf. (97271)
- 25 inoculated.tw,kf. (153237)
- 26 immuni#ed.tw,kf. (119849)
- 27 post-vaccinat*.tw,kf. (11845)
- 28 post-inoculat*.tw,kf. (11629)
- 29 post-immuni*.tw,kf. (3943)

30 ((after or already or full or fully or post or received) adj3 (immunis* or immuniz* or immunity or inoculat* or vaccin*)).tw,kf. (185626)

- 31 (status* adj3 (immunis* or immuniz* or immunity or inoculat* or vaccin*)).tw,kf. (17479)
- 32 or/24-31 [VACCINATED] (472108)
- 33 23 and 32 (5627)
- 34 Health Surveys/ (249807)
- 35 ((health or population?) adj3 survey?).tw,kf. (175676)
- 36 ((disease* or pandemic*) adj3 (monitor* or survey?)).tw,kf. (54464)
- 37 ((COVID or COVID-19 or COVID19) adj3 (monitor* or survey?)).tw,kf. (1920)
- 38 ((coronavirus* or corona virus*) adj3 (monitor* or survey?)).tw,kf. (216)

39 ((2019-nCoV or nCoV or n-CoV or SARS-CoV-2 or SARS-CoV2 or SARSCoV-2 or SARSCoV2 or SARS2) adj3 (monitor* or survey?)).tw,kf. (449)

- 40 ((BNT162 or BNT162-01 or BNT162a1 or BNT162b1 or BNT162b2 or BNT162c2) adj3 (monitor* or survey?)).tw,kf. (3)
- 41 ((alpha or beta or delta or gamma) adj3 variant? adj3 (monitor* or survey*)).tw,kf. (6)
- 42 *Epidemiological Methods/ (6485)
- 43 Epidemiological Monitoring/ (10263)
- 44 (epidemiolog* adj3 monitor*).tw,kf. (3222)



- 45 Seroepidemiologic Studies/ (26333)
- 46 ((seroepidemiol* or sero-epidemiol*) adj3 (monitor* or survey* or study or studies)).tw,kf. (7085)
- 47 (seromonitor* or sero-monitor* or serological monitor*).tw,kf. (568)
- 48 (seroprevalen* or sero-prevalen* or serological prevalen*).tw,kf. (46051)
- 49 (serosurveillan* or sero-surveillan*).tw,kf. (1271)
- 50 (serosurvey? or sero-survey? or serological survey?).tw,kf. (8888)
- 51 Wastewater-Based Epidemiological Monitoring/ (2419)
- 52 Waste Water/ (50317)
- 53 (sewage* or wastewater or waste water).tw,kf. (179449)
- 54 Norman score?.tw,kf. (84)
- 55 Data Collection/ (305772)
- 56 ((collect* or monitor*) adj3 data).tw,kf. (1017644)
- 57 Public Health Practice/ (70070)
- 58 ((community health or public health) adj3 (practice? or activit* or endeavo?r?)).tw,kf. (15598)
- 59 exp Population Surveillance/ (306931)
- 60 surveillance*.tw,kf. (471636)
- 61 (biosurveillance* or bio-surveillance*).tw,kf. (688)
- 62 Mass Screening/ (167946)
- 63 screening.tw,kf. (1426501)
- 64 ((mass or population*) adj3 screen*).tw,kf. (56691)
- 65 (screen* or detect* or identif* or recogni*).ti,kf. (2180317)
- 66 ((early or earlier or earliest or ongoing or regular*) adj5 (screen* or detect* or identif* or recogni*)).tw,kf. (528091)
- 67 (case finding? or casefinding?).tw,kf. (13173)
- 68 Metagenomics/ (24172)
- 69 (ecogenomic* or eco-genomic* or metagenomic* or meta-genomic*).tw,kf. (31596)
- 70 ((communit* or ecologic* or environment* or population) adj3 genomic*).tw,kf. (11485)



- 71 COVID-19 Testing/ (5913)
- 72 ((COVID or COVID-19 or COVID19) adj3 test*).tw,kf. (7582)
- 73 ((coronavirus* or corona virus*) adj3 test*).tw,kf. (1002)

74 ((2019-nCoV or nCoV or n-CoV or SARS-CoV-2 or SARS-CoV2 or SARSCoV-2 or SARSCoV2 or SARS2) adj3 test*).tw,kf. (7627)

- 75 ((BNT162 or BNT162-01 or BNT162a1 or BNT162b1 or BNT162b2 or BNT162c2) adj3 test*).tw,kf. (8)
- 76 ((alpha or beta or delta or gamma) adj3 variant? adj3 test*).tw,kf. (41)
- 77 (serologic* adj3 test*).tw,kf. (50026)
- 78 Point-of-Care Testing/ (18292)

79 ((point-of-care or bedside? or bed side? or POC or rapid*) adj3 (assay? or immunoassay? or immuno-assay? or detect* or diagnos* or screen* or test*)).tw,kf. (225556)

- 80 (field adj3 (assay? or immunoassay? or immuno-assay? or detect* or diagnos* or screen* or test*)).tw,kf. (74754)
- 81 POCT.tw,kf. (5011)
- 82 (rapid adj3 (antigen* adj3 (assay? or immunoassay? or immuno-assay? or test*))).tw,kf. (3251)
- 83 (random* adj3 (assay? or immunoassay? or immuno-assay? or detect* or diagnos* or screen* or test*)).tw,kf. (80902)
- 84 (random* adj3 sampl*).tw,kf. (173755)
- 85 (pool* adj3 sampl*).tw,kf. (18948)
- 86 COVID-19/ep [epidemiology] (14412)
- 87 Coronavirus Infections/ep [epidemiology] (23494)
- 88 Incidence/ (742644)
- 89 Prevalence/ (1098179)
- 90 (incidence or prevalen*).tw,kf. (3890564)
- 91 or/34-90 [SURVEILLANCE BROAD] (9638102)
- 92 33 and 91 (1620)
- 93 exp Animals/ not Humans/ (16106641)
- 94 92 not 93 [ANIMAL-ONLY REMOVED] (1213)
- 95 limit 94 to yr="2020-current" (1045)



- 96 95 use ppez [MEDLINE RECORDS] (557)
- 97 coronavirus disease 2019/ (204518)
- 98 severe acute respiratory syndrome coronavirus 2/ (98155)
- 99 Coronavirinae/ (4902)
- 100 Betacoronavirus/ (40986)
- 101 coronavirus infection/ (58134)
- 102 (COVID-19 or COVID19).tw,kw. (258126)
- 103 ((coronavirus* or corona virus*) and (hubei or wuhan or beijing or shanghai)).tw,kw. (9934)
- 104 (wuhan adj5 virus*).tw,kw. (542)
- 105 (2019-nCoV or 19nCoV or 2019nCoV).tw,kw. (3494)
- 106 (nCoV or n-CoV or "CoV 2" or CoV2).tw,kw. (91701)

107 (SARS-CoV-2 or SARS-CoV2 or SARSCoV-2 or SARSCoV2 or SARS2 or SARS-2 or severe acute respiratory syndrome coronavirus 2).tw,kw. (99684)

108 (2019-novel CoV or Sars-coronavirus2 or Sars-coronavirus-2 or SARS-like coronavirus* or ((novel or new or nouveau) adj2 (CoV or nCoV or covid or coronavirus* or corona virus or Pandemi*2)) or (coronavirus* and pneumonia)).tw,kw. (36564)

- 109 (novel coronavirus* or novel corona virus* or novel CoV).tw,kw. (18583)
- 110 ((coronavirus* or corona virus*) adj2 "2019").tw,kw. (58746)
- 111 ((coronavirus* or corona virus*) adj2 "19").tw,kw. (9103)
- 112 ("coronavirus 2" or "corona virus 2").tw,kw. (29862)
- 113 (OC43 or NL63 or 229E or HKU1 or HCoV* or Sars-coronavirus*).tw,kw. (7753)
- 114 (coronavirus* or corona virus*).ti. (43970)
- 115 ("B.1.1.7" or "B.1.351" or "B.1.617" or "B.1.427" or "B.1.429").tw,kw. (629)
- 116 ("P.1" and (Brazil* or variant?)).tw,kw. (3418)
- 117 ((alpha or beta or delta or gamma) adj3 variant?).tw,kw. (11631)
- 118 or/97-117 [COVID-19] (338798)
- 119 vaccinated.tw,kw. (97263)
- 120 inoculated.tw,kw. (153233)



- 121 immuni#ed.tw,kw. (119853)
- 122 post-vaccinat*.tw,kw. (11879)
- 123 post-inoculat*.tw,kw. (11625)
- 124 post-immuni*.tw,kw. (3945)

125 ((after or already or full or fully or post or received) adj3 (immunis* or immuniz* or immunity or inoculat* or vaccin*)).tw,kw. (185537)

- 126 (status* adj3 (immunis* or immuniz* or immunity or inoculat* or vaccin*)).tw,kw. (17522)
- 127 or/119-126 [VACCINATED] (472056)
- 128 118 and 127 (5590)
- 129 health survey/ (266784)
- 130 ((health or population?) adj3 survey?).tw,kw. (180468)
- 131 disease surveillance/ (30911)
- 132 ((disease* or pandemic*) adj3 (monitor* or survey?)).tw,kw. (56302)
- 133 ((COVID or COVID-19 or COVID19) adj3 (monitor* or survey?)).tw,kw. (2268)
- 134 ((coronavirus* or corona virus*) adj3 (monitor* or survey?)).tw,kw. (283)

135 ((2019-nCoV or nCoV or nCoV or SARS-CoV-2 or SARS-CoV2 or SARSCoV-2 or SARSCoV2 or SARS2) adj3 (monitor* or survey?)).tw,kw. (523)

- 136 ((BNT162 or BNT162-01 or BNT162a1 or BNT162b1 or BNT162b2 or BNT162c2) adj3 (monitor* or survey?)).tw,kw. (4)
- 137 ((alpha or beta or delta or gamma) adj3 variant? adj3 (monitor* or survey*)).tw,kw. (6)
- 138 epidemiological data/ (34565)
- 139 epidemiological monitoring/ (10263)
- 140 infection rate/ (33957)
- 141 (epidemiolog* adj3 monitor*).tw,kw. (3329)
- 142 seroepidemiology/ (4490)
- 143 ((seroepidemiol* or sero-epidemiol*) adj3 (monitor* or survey* or study or studies)).tw,kw. (7224)
- 144 (seromonitor* or sero-monitor* or serological monitor*).tw,kw. (575)
- 145 (seroprevalen* or sero-prevalen* or serological prevalen*).tw,kw. (46903)



- 146 (serosurveillan* or sero-surveillan*).tw,kw. (1338)
- 147 (serosurvey? or sero-survey? or serological survey?).tw,kw. (9023)
- 148 waste water/ (50317)
- 149 (sewage* or wastewater or waste water).tw,kw. (182355)
- 150 Norman score?.tw,kw. (84)
- 151 information processing/ (254616)
- 152 ((collect* or monitor*) adj3 data).tw,kw. (1017125)
- 153 ((community health or public health) adj3 (practice? or activit* or endeavo?r?)).tw,kw. (15937)
- 154 surveillance*.tw,kw. (477847)
- 155 (biosurveillance* or bio-surveillance*).tw,kw. (735)
- 156 screening/ (289977)
- 157 mass screening/ (167946)
- 158 screening.tw,kw. (1440549)
- 159 ((mass or population*) adj3 screen*).tw,kw. (58731)
- 160 (screen* or detect* or identif* or recogni*).ti. (2128877)
- 161 ((early or earlier or earliest or ongoing or regular*) adj5 (screen* or detect* or identif* or recogni*)).tw,kw. (529117)
- 162 (case finding? or casefinding?).tw,kw. (13335)
- 163 metagenomics/ (24172)
- 164 (ecogenomic* or eco-genomic* or metagenomic* or meta-genomic*).tw,kw. (32991)
- 165 ((communit* or ecologic* or environment* or population) adj3 genomic*).tw,kw. (11715)
- 166 immunoassay/ (102667)
- 167 antibody detection/ (44387)
- 168 ((COVID or COVID-19 or COVID19) adj3 test*).tw,kw. (7790)
- 169 ((coronavirus* or corona virus*) adj3 test*).tw,kw. (1062)

170 ((2019-nCoV or nCoV or nCoV or SARS-CoV-2 or SARS-CoV2 or SARSCoV-2 or SARSCoV2 or SARS2) adj3 test*).tw,kw. (7742)

171 ((BNT162 or BNT162-01 or BNT162a1 or BNT162b1 or BNT162b2 or BNT162c2) adj3 test*).tw,kw. (8)



- 172 ((alpha or beta or delta or gamma) adj3 variant? adj3 test*).tw,kw. (41)
- 173 (serologic* adj3 test*).tw,kw. (50287)
- 174 point of care testing/ (18292)

175 ((point-of-care or bedside? or bed side? or POC or rapid*) adj3 (assay? or immunoassay? or immuno-assay? or detect* or diagnos* or screen* or test*)).tw,kw. (226660)

- 176 (field adj3 (assay? or immunoassay? or immuno-assay? or detect* or diagnos* or screen* or test*)).tw,kw. (75079)
- 177 POCT.tw,kw. (5137)
- 178 (rapid adj3 (antigen* adj3 (assay? or immunoassay? or immuno-assay? or test*))).tw,kw. (3272)
- (random* adj3 (assay? or immunoassay? or immuno-assay? or detect* or diagnos* or screen* or test*)).tw,kw. (88476)
- 180 random sample/ (13341)
- 181 sampling/ (79889)
- 182 (random* adj3 sampl*).tw,kw. (179585)
- 183 (pool* adj3 sampl*).tw,kw. (18959)
- 184 coronavirus disease 2019/ep [epidemiology] (25103)
- 185 coronavirus infection/ep [epidemiology] (23535)
- 186 incidence/ (742644)
- 187 prevalence/ (1098179)
- 188 (incidence or prevalen*).tw,kw. (3900074)
- 189 or/129-188 [SURVEILLANCE BROAD] (9710465)
- 190 128 and 189 (1666)

191 exp animal/ or exp animal experimentation/ or exp animal model/ or exp animal experiment/ or nonhuman/ or exp vertebrate/ (53905444)

- 192 exp human/ or exp human experimentation/ or exp human experiment/ (42359723)
- 193 191 not 192 (11547438)
- 194 190 not 193 [ANIMAL-ONLY REMOVED] (1263)
- 195 limit 194 to yr="2020-current" (1090)
- 196 195 use oemezd [EMBASE RECORDS] (451)



- 197 COVID-19/ (85559)
- 198 SARS-CoV-2/ (81242)
- 199 Coronavirus/ (13278)
- 200 Betacoronavirus/ (40986)
- 201 Coronavirus Infections/ (57260)
- 202 (COVID-19 or COVID19).ti,ab,kw. (258067)
- 203 ((coronavirus* or corona virus*) and (hubei or wuhan or beijing or shanghai)).ti,ab,kw. (9910)
- 204 (wuhan adj5 virus*).ti,ab,kw. (535)
- 205 (2019-nCoV or 19nCoV or 2019nCoV).ti,ab,kw. (3468)
- 206 (nCoV or n-CoV or "CoV 2" or CoV2).ti,ab,kw. (91681)

207 (SARS-CoV-2 or SARS-CoV2 or SARSCoV-2 or SARSCoV2 or SARS2 or SARS-2 or severe acute respiratory syndrome coronavirus 2).ti,ab,kw. (99672)

208 (2019-novel CoV or Sars-coronavirus2 or Sars-coronavirus-2 or SARS-like coronavirus* or ((novel or new or nouveau) adj2 (CoV or nCoV or covid or coronavirus* or corona virus or Pandemi*2)) or (coronavirus* and pneumonia)).ti,ab,kw. (36536)

- 209 (novel coronavirus* or novel corona virus* or novel CoV).ti,ab,kw. (18558)
- 210 ((coronavirus* or corona virus*) adj2 "2019").ti,ab,kw. (58733)
- 211 ((coronavirus* or corona virus*) adj2 "19").ti,ab,kw. (9089)
- 212 ("coronavirus 2" or "corona virus 2").ti,ab,kw. (29846)
- 213 (OC43 or NL63 or 229E or HKU1 or HCoV* or Sars-coronavirus*).ti,ab,kw. (7730)
- 214 (coronavirus* or corona virus*).ti. (43970)
- 215 ("B.1.1.7" or "B.1.351" or "B.1.617" or "B.1.427" or "B.1.429").ti,ab,kw. (627)
- 216 ("P.1" and (Brazil* or variant?)).ti,ab,kw. (3403)
- 217 ((alpha or beta or delta or gamma) adj3 variant?).ti,ab,kw. (11631)
- 218 or/197-217 [COVID-19] (330858)
- 219 vaccinated.ti,ab,kw. (97171)
- 220 inoculated.ti,ab,kw. (153204)
- 221 immuni#ed.ti,ab,kw. (119795)



- 222 post-vaccinat*.ti,ab,kw. (11858)
- 223 post-inoculat*.ti,ab,kw. (11624)
- 224 post-immuni*.ti,ab,kw. (3940)

((after or already or full or fully or post or received) adj3 (immunis* or immuniz* or immunity or inoculat* or vaccin*)).ti,ab,kw. (185426)

- 226 (status* adj3 (immunis* or immuniz* or immunity or inoculat* or vaccin*)).ti,ab,kw. (17468)
- 227 or/219-226 [VACCINATED] (471883)
- 228 218 and 227 (5617)
- 229 Health Surveys/ (249807)
- 230 ((health or population?) adj3 survey?).ti,ab,kw. (179817)
- 231 ((disease* or pandemic*) adj3 (monitor* or survey?)).ti,ab,kw. (56234)
- 232 ((COVID or COVID-19 or COVID19) adj3 (monitor* or survey?)).ti,ab,kw. (2268)
- 233 ((coronavirus* or corona virus*) adj3 (monitor* or survey?)).ti,ab,kw. (283)

234 ((2019-nCoV or nCoV or nCoV or SARS-CoV-2 or SARS-CoV2 or SARSCoV-2 or SARSCoV2 or SARS2) adj3 (monitor* or survey?)).ti,ab,kw. (523)

((BNT162 or BNT162-01 or BNT162a1 or BNT162b1 or BNT162b2 or BNT162c2) adj3 (monitor* or survey?)).ti,ab,kw.
 (4)

- 236 ((alpha or beta or delta or gamma) adj3 variant? adj3 (monitor* or survey*)).ti,ab,kw. (6)
- 237 *Epidemiological Methods/ (6485)
- 238 Epidemiological Monitoring/ (10263)
- 239 (epidemiolog* adj3 monitor*).ti,ab,kw. (3326)
- 240 Seroepidemiologic Studies/ (26333)
- 241 ((seroepidemiol* or sero-epidemiol*) adj3 (monitor* or survey* or study or studies)).ti,ab,kw. (7220)
- 242 (seromonitor* or sero-monitor* or serological monitor*).ti,ab,kw. (574)
- 243 (seroprevalen* or sero-prevalen* or serological prevalen*).ti,ab,kw. (46880)
- 244 (serosurveillan* or sero-surveillan*).ti,ab,kw. (1338)
- 245 (serosurvey? or sero-survey? or serological survey?).ti,ab,kw. (9021)
- 246 Wastewater-Based Epidemiological Monitoring/ (2419)



- 247 Waste Water/ (50317)
- 248 (sewage* or wastewater or waste water).ti,ab,kw. (182349)
- 249 Norman score?.ti,ab,kw. (81)
- 250 Data Collection/ (305772)
- 251 ((collect* or monitor*) adj3 data).ti,ab,kw. (1015431)
- 252 Public Health Practice/ (70070)
- 253 ((community health or public health) adj3 (practice? or activit* or endeavo?r?)).ti,ab,kw. (15865)
- 254 exp Population Surveillance/ (306931)
- 255 surveillance*.ti,ab,kw. (477093)
- 256 (biosurveillance* or bio-surveillance*).ti,ab,kw. (735)
- 257 Mass Screening/ (167946)
- 258 screening.ti,ab,kw. (1436256)
- 259 ((mass or population*) adj3 screen*).ti,ab,kw. (58593)
- 260 (screen* or detect* or identif* or recogni*).ti. (2128877)
- 261 ((early or earlier or earliest or ongoing or regular*) adj5 (screen* or detect* or identif* or recogni*)).ti,ab,kw. (526276)
- 262 (case finding? or casefinding?).ti,ab,kw. (13278)
- 263 Metagenomics/ (24172)
- 264 (ecogenomic* or eco-genomic* or metagenomic* or meta-genomic*).ti,ab,kw. (32988)
- 265 ((communit* or ecologic* or environment* or population) adj3 genomic*).ti,ab,kw. (11715)
- 266 COVID-19 Testing/ (5913)
- 267 ((COVID or COVID-19 or COVID19) adj3 test*).ti,ab,kw. (7783)
- 268 ((coronavirus* or corona virus*) adj3 test*).ti,ab,kw. (1061)

269 ((2019-nCoV or nCoV or nCoV or SARS-CoV-2 or SARS-CoV2 or SARSCoV-2 or SARSCoV2 or SARS2) adj3 test*).ti,ab,kw. (7733)

- 270 ((BNT162 or BNT162-01 or BNT162a1 or BNT162b1 or BNT162b2 or BNT162c2) adj3 test*).ti,ab,kw. (8)
- 271 ((alpha or beta or delta or gamma) adj3 variant? adj3 test*).ti,ab,kw. (41)
- 272 (serologic* adj3 test*).ti,ab,kw. (50216)



273 Point-of-Care Testing/ (18292)

274 ((point-of-care or bedside? or bed side? or POC or rapid*) adj3 (assay? or immunoassay? or immuno-assay? or detect* or diagnos* or screen* or test*)).ti,ab,kw. (226456)

- (field adj3 (assay? or immunoassay? or immuno-assay? or detect* or diagnos* or screen* or test*)).ti,ab,kw. (74971)
- 276 POCT.ti,ab,kw. (5130)
- 277 (rapid adj3 (antigen* adj3 (assay? or immunoassay? or immuno-assay? or test*))).ti,ab,kw. (3261)

(random* adj3 (assay? or immunoassay? or immuno-assay? or detect* or diagnos* or screen* or test*)).ti,ab,kw.(87480)

- 279 (random* adj3 sampl*).ti,ab,kw. (178562)
- 280 (pool* adj3 sampl*).ti,ab,kw. (18914)
- 281 COVID-19/ep [epidemiology] (14412)
- 282 Coronavirus Infections/ep [epidemiology] (23494)
- 283 Incidence/ (742644)
- 284 Prevalence/ (1098179)
- 285 (incidence or prevalen*).ti,ab,kw. (3893916)
- 286 or/229-285 [SURVEILLANCE BROAD] (9644667)
- 287 228 and 286 (1610)
- 288 exp Animals/ not Humans/ (16106641)
- 289 287 not 288 [ANIMAL-ONLY REMOVED] (1204)
- 290 limit 289 to yr="2020-current" (1050)
- 291 290 use coch [CDSR RECORDS] (0)
- 292 290 use cctr [CENTRAL] (78)
- 293 96 or 196 or 291 or 292 [ALL DATABASES] (1086)
- 294 remove duplicates from 293 (737) [TOTAL UNIQUE RECORDS]
- 295 294 use ppez [MEDLINE UNIQUE RECORDS] (541)
- 296 294 use oemezd [EMBASE UNIQUE RECORDS] (126)
- 297 294 use coch [CDSR UNIQUE RECORDS] (0)



298 294 use cctr [CENTRAL UNIQUE RECORDS] (70)

Web of Science

29 <u>416</u> #27 AND #15

Refined by: PUBLICATION YEARS: (2021 OR 2020)

Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years

28 <u>543</u> #27 AND #15

Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years

27 <u>5,898,342</u> #26 OR #25 OR #24 OR #23 OR #22 OR #21 OR #20 OR #19 OR #18 OR #17 OR #16

Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years

26 <u>1,830,229</u> TOPIC: (incidence or prevalen*)

Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years

25 <u>153,072</u> TOPIC: (random* NEAR/3 assay*) OR TOPIC: (random* NEAR/3 immunoassay*) OR TITLE: (random** NEAR/3 "immuno-assay") OR TOPIC: (random* NEAR/3 "immuno-assays") OR TOPIC: (random* NEAR/3 detect*) OR TOPIC: (random* NEAR/3 diagnos*) OR TOPIC: (random* NEAR/3 screen*) OR TOPIC: (random* NEAR/3 test*) OR TOPIC: (random* NEAR/3 sampl*) OR TOPIC: (pool* NEAR/3 sampl*)

Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years

24 57.001 TOPIC: (antigen* NEAR/3 assay*) OR TOPIC: (antigen* NEAR/3 immunoassay*) OR TITLE: (antigen* NEAR/3 "immuno-assay") OR TOPIC: (antigen* NEAR/3 "immuno-assays") OR TOPIC: (antigen* NEAR/3 detect*) OR TOPIC: (antigen* NEAR/3 diagnos*) OR TOPIC: (antigen* NEAR/3 screen*) OR TOPIC: (antigen* NEAR/3 test*) OR TOPIC: (POCT)

Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years

23 <u>123,606</u> TS=(field NEAR/3 assay*) OR TS=(field NEAR/3 immunoassay") OR TS=(field NEAR/3 "immunoassays") OR TS=(field NEAR/3 detect*) OR TS=(field NEAR/3 diagnos*) OR TS=(field NEAR/3 screen*) OR TS=(field NEAR/3 test*)



22 <u>138,900</u>

care" or bedside* or "bed side" or "bed sides" or POC or rapid*) NEAR/3 assay*) OR TS=(("p oint-ofcare" or bedside* or "bed side" or "bed sides" or POC or rapid*) NEAR/3 immunoassay*) OR TS=(("point-ofcare" or bedside* or "bed side" or "bed sides" or POC or rapid*) NEAR/3 "immunoassay") OR TS=(("point-ofcare" or bedside* or "bed side" or "bed sides" or POC or rapid*) NEAR/3 "immunoassays") OR TS=(("point-ofcare" or bedside* or "bed side" or "bed sides" or POC or rapid*) NEAR/3 "immunoassays") OR TS=(("point-ofcare" or bedside* or "bed side" or "bed sides" or POC or rapid*) NEAR/3 detect*) OR TS=(("p oint-ofcare" or bedside* or "bed side" or "bed sides" or POC or rapid*) NEAR/3 diagnos*) OR TS=(("p oint-ofcare" or bedside* or "bed side" or "bed sides" or POC or rapid*) NEAR/3 diagnos*) OR TS=(("p oint-ofcare" or bedside* or "bed side" or "bed sides" or POC or rapid*) NEAR/3 test*)

Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years

21 24,382 TS=((COVID or "COVID-

TS=(("point-of-

19" or COVID19) NEAR/3 test*) OR TS=((coronavirus* or "corona virus" or "corona viruses") N EAR/3 test*) OR TS=(("2019-nCoV" or nCoV or "n-CoV" or "SARS-CoV-2" or "SARS-CoV-2" or "SARSCoV-2" or SARSCoV-2" or "SARS-CoV-2" or "SARS-CoV-2" or SARSCoV-2" OR TS=(("alpha variant" or "alpha variants" or "beta variants" or "beta variants" or "delta variant" or "delta variants" or "gamma variant" or "gamma variants") NEAR/3 test*) OR TS=(serologic* NEAR/3 test*)

Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years

20 2.865,858 TOPIC: (screening) OR TOPIC: ((mass or population*) NEAR/3 screen*) OR TITLE: (screen* or detect* or identif* or recogni*) OR TOPIC: ((early or earlier or earliest or ongoing or regular*) NEAR/5 (screen* or detect* or identif* or recogni*)) OR TOPIC: ("case finding" or "case findings" or casefinding*) OR TOPIC: (ecogenomic* or (eco NEAR/0 genomic*)) OR TOPIC: ((communit* or ecologic* or environment* or population) NEAR/3 genomic*)

Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years

19 <u>1,236,678</u> TOPIC: (sewage* or wastewater or "waste water") OR TOPIC: ("Norman score" or "Norman scores") OR TOPIC: ((collect* or monitor*) NEAR/3 data) OR TOPIC: (("community health" or "public health") NEAR/3 (practice* or activit* or endeavour* or endeavor*)) OR TOPIC: (surveillance*) OR TOPIC: (biosurveillance* or "bio-surveillance" or "bio-surveillances")

Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years

18 <u>32,874</u> TOPIC: ((seroepidemiol* or "sero-epidemiology" or "sero-epidemiologic" or "sero-epidemiological") NEAR/3 monitor*) OR TOPIC: ((seroepidemiol* or "sero-epidemiology" or "sero-epidemiologic" or "sero-epidemiologic") NEAR/3 survey*) OR TOPIC: ((seroepidemiol* or "sero-epidemiol* or "sero-epidem



epidemiology" or "sero-epidemiologic" or "seroepidemiological") NEAR/3 study) OR TOPIC: ((seroepidemiol* or "sero-epidemiology" or "seroepidemiologic" or "sero-epidemiological") NEAR/3 studies) OR TOPIC: (seromonitor* or (sero NEAR/0 monitor*) or (serological NEAR/0 monitor*)) OR TOPIC: (seroprevalen* or (sero NEAR/0 prevalen*) or (serological NEAR/0 prevalen*)) OR TOPIC: (serosurveillan* or (sero NEAR/0 surveillan*)) OR TOPIC: (serosurvey* or (sero NEAR/0 survey*) or (serological NEAR/0 survey*))

Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years

17 261 TOPIC: (("2019-nCoV" or nCoV or "n-CoV" or "SARS-CoV-2" or "SARS-CoV2" or "SARSCoV-2" or SARSCoV2 or SARS2) NEAR/3 monitor*) OR TOPIC: (("2019-nCoV" or nCoV or "n-CoV" or "SARS-CoV-2" or "SARS-CoV2" or "SARS-CoV2" or "SARSCoV-2" or SARSCoV-2" or "SARS-CoV2" or "SARS-COV" or "SARS-COV2" or "SARS-COV2" or "SA

Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years

16 <u>143,345</u> TOPIC: ((health or population*) NEAR/3 survey*) OR TOPIC: ((disease* or pandemic*) NEAR/3 monitor*) OR TOPIC: ((disease* or pandemic*) NEAR/3 survey*) OR TOPIC: ((COVID or "COVID-19" or COVID19) NEAR/3 monitor*) OR TOPIC: ((COVID or "COVID-19" or COVID19) NEAR/3 survey*) OR TOPIC: ((coronavirus* or "corona virus" or "corona viruses") NEAR/3 monitor*) OR TOPIC: ((coronavirus* or "corona virus" or "corona viruses") NEAR/3 survey*)

Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years

#15 <u>1,960</u> #14 AND #13

Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years

14 229,157 TOPIC: (vaccinated or inoculated or immunised or immunized) OR TOPIC: (post NEAR/0 (vaccinat* or inoculat* or inoculat* or immuni*)) OR TOPIC: ((after or already or full or fully or post or received) NEAR/3 (immunis* or immuniz* or immunity or inoculat* or vaccin*)) OR TOPIC: (status* NEAR/3 (immunis* or immuniz* or immunity or inoculat* or vaccin*))

Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years

#13 163,669 #12 OR #11 OR #10 OR #9 OR #8 OR #7 OR #6 OR #5 OR #4 OR #3 OR #2 OR #1



12 <u>16,068</u> TOPIC: ("B.1.1.7" or "B.1.351" or "B.1.617" or "B.1.427" or "B.1.429") OR TOPIC: ("P.1" and (Brazil* or variant*)) OR TOPIC: ((alpha or beta or delta or gamma) NEAR/3 variant*)

Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years

11 20,724 TI=(coronavirus* or "corona virus" or "corona viruses")

Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years

- # 10 <u>5,592</u> TS=(OC43 or NL63 or 229E or HKU1 or HCoV* or "Sars-coronavirus") Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years
- # 9 <u>14,471</u> TS=("coronavirus 2" or "corona virus 2" or "coronavirus 2019" or "coronavirus 19") Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years
- # 8 8,366 TI=((coronavirus* or "corona virus") AND ("2019" or "19"))
 Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years
- # 7 8.477 TS=("novel coronavirus" or "novel corona virus" or "novel CoV") Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years
- # 6 <u>340</u> TS=("2019-novel CoV" or "Sars-coronavirus2" or "Sars-coronavirus-2" or "SARS-like coronavirus") Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years
- #5 <u>41,380</u> TS=("SARS-CoV-2" or "SARS-CoV2" or "SARSCoV-2" or SARSCoV2 or SARS2 or "SARS-2" or "severe acute respiratory syndrome coronavirus 2")

Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years

- # 4 <u>40,821</u> TS=("2019-nCoV" or 19nCoV or 2019nCoV or nCoV or "n-CoV" or "CoV 2" or CoV2) Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years
- # 3 <u>24</u> TS="Wuhan virus"

- # 2 <u>5,748</u> TS=((coronavirus* or corona virus*) and (hubei or wuhan or beijing or shanghai)) Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years
- # 1 <u>127,774</u> TS=("COVID-19" or COVID19)





Appendix B: Additional Details on International Guidance

Table 6: Summary of Included Guidance

Country	Institute/Author	Scope, Setting, Evidence	Surveillance Method Used	Summary of Guidance
		Ju	ne 2021	
Australia (Southern)	Government of South Australia - SA Health ⁵²	Scope: Regional Setting: Community Level of Evidence: Unclear	Wastewater surveillance Stated reason for use: Testing wastewater can help provide an early warning signal of COVID-19 infections in people living in a particular wastewater catchment area.	Wastewater testing is done to support the State's response to COVID-19; helps to provide an early warning signal of COVID-19 infections in people living in a particular wastewater catchment area.
Australia (Western)	Government of Western Australia - Department of Health ⁵³	Scope: Regional Setting: Community Level of Evidence: Unclear	Wastewater surveillance Stated reason for use: Wastewater testing will complement – but cannot replace – other kinds of COVID-19 testing, including nose and throat swabs. Wastewater testing indicates if COVID- 19 may be present in the broader community.	The wastewater testing program complements other work already being done to monitor COVID-19, including testing of individual people using nose and throat swabs, and, together, these help inform WA Health's response to the pandemic. Samples are taken from six metropolitan locations and 10 regional localities.
Germany	Federal Ministry of Health ⁵⁴	Scope: National Setting: Community Level of Evidence: Unclear	Digital support for health authorities, digital symptom diary, contact management Stated reason for use: Enable nationwide, secure and fast electronic reporting and information processing with regard to positive SARS-CoV2. In this way, the effort for the reporting laboratories and the responsible health authorities and state authorities is to be reduced, and infection events that occur are to be contained by the possibility of introducing targeted infection protection measures more quickly.	 German Electronic Reporting and Information System for Infection Protection (DEMIS) for reporting laboratory confirmed cases. Digital symptom diary application (Climedo) which is used to conduct daily surveys of contacts of persons with COVID-19. Surveillance Outbreak Response Management and Analysis System (SORMAS): For efficient identification of contacts.
		Ma	ay 2021	







Country	Institute/Author	Scope, Setting, Evidence	Surveillance Method Used	Summary of Guidance
UK	Public Health England ⁵⁵	Scope: National Setting: School, healthcare setting, community Level of Evidence: Evidence informed	Serosurveillance, population PCR Stated reason for use: Children represent a small proportion of the total number of confirmed COVID-19 cases. There are limited data on childhood SARS-CoV-19infections, especially from Europe. Public Health England (PHE) along with NHS partners and academic collaborators has implemented a number of ongoing surveillance programmes to monitor the course, progression and outcomes of COVID-19 in children.	 Surveillance methods include: sKIDs PLUS: COVID-19 surveillance in secondary schools (2020/21 academic year): Participants in 20 secondary schools will have nasal swabs, saliva and blood samples for virus and antibody testing at recruitment and end of term. Outbreak surveillance in educational settings (Ongoing): PHE has been monitoring cases, clusters and outbreaks in educational settings since the reopening of schools on 1 June 2020. School infection surveys: PHE conducting a large prospective school survey of staff and students in up to 150 schools across England. Electronic notification of Cases: PHE receives electronic notifications of all confirmed COVID-19 cases from NHS hospital laboratories in England through the Second-Generation Surveillance System (SGSS). Clinical follow up of laboratory-confirmed cases in neonates up to 28 days of age: Pediatricians across the UK and Ireland will receive weekly emails from the British Paediatric Surveillance Unit (BPSU) team to report whether they have managed a case of neonatal COVID-19 in the previous week. Those confirming a case will be asked to complete a short clinical questionnaire. RAPID-19 Study (COVID in children of HCWs): PHE is working with teams across the UK to conduct surveillance in children of healthcare workers across 5 cities. Samples will be taken for SARS-COV-2 antibodies at recruitment, around 8 weeks later and 4 to 6 months later. This will allow us to monitor how much







Country	Institute/Author	Scope, Setting, Evidence	Surveillance Method Used	Summary of Guidance
				the children have been exposed to the virus between the different testing periods.
USA	CDC ⁵⁶	Scope: National Setting: Community Level of Evidence: Evidence informed	Population genomic screening Stated reason for use: Improve our understanding of which variants are circulating the US, how quickly variants emerge, and which variants are the most important to characterize and track in the terms of health.	 CDC contracted large commercial diagnostic labs to sequence samples across the US to sequence SARS- CoV-2 genomes. Goal is to identify and characterize variant viruses (either new ones identified in the US or those already identified abroad) and to investigate how variants impact COVID-19 disease severity and the effectiveness of vaccines, treatment, and diagnostic tests.
		А	pril 2021	
Australia	Communicable Diseases Network Australia ⁵⁷	Scope: National Setting: Community Level of Evidence: Evidence informed	Case-based reporting, surveillance of outbreaks and clusters, targeted active case finding, syndromic and sentinel surveillance, serosurveillance, virus genomics, monitoring of personal behaviours State reason for use: Australia continues to follow a suppression strategy in response to COVID-19. Each disease surveillance goal contributes information, via key indicators, that support strategic and operational decision-making by national and jurisdictional governments and public health authorities.	 Surveillance strategies include: Monitoring the characteristics and time trends of COVID-19 cases to support planning and evaluation of prevention activities and testing services. Providing updates on the SARS-CoV-2 transmission potential and forecasts of epidemic activity to support planning and evaluation of prevention activities. Characterizing clusters and secondary cases to facilitate management within and across jurisdictions and inform targeted control strategies. Monitoring testing counts for SARS-CoV-2 and to provide denominator to track how effectively testing is being utilized and for an indication of the positivity yield. Monitoring community trends in "fever/acute respiratory illness (ARI)" and the proportion tested and attributable to SARS-CoV-2 to assess the extent of community transmission and the effectiveness of public health measures aimed at both prevention and case detection. Determining seroprevalence rates of SARS-CoV-2 by population group and geographic location to







Country	Institute/Author	Scope, Setting, Evidence	Surveillance Method Used	Summary of Guidance
				 complement our understanding of population transmission of SARS-CoV-2 from other surveillance data. Reporting on strategically targeted asymptomatic testing of selected populations potentially at higher risk of exposure. Monitoring the characteristics of deaths due to COVID- 19 as a key measure of the health impact of the disease in our community. Describing the clinical severity of COVID-19 cases to allow prediction of health resource use and to standardize models of care, and characterizing risk factors for serious infection to allow for targeted public health measures. Assessing case detection and contact tracing to understand capacity to detect and interrupt chains of transmission and to support resource planning. Monitoring adherence to recommended behavioural practices to support planning and evaluation of prevention activities. Measuring impacts on the tertiary health care system to contribute to forecasts of capacity requirements to redirect resources as required.
France	Sante Publique France ⁵⁸	Scope: National, outside of Brittany Setting: Community Level of Evidence: Unclear	Population PCR screening, with sequencing of SA variant cases Stated reason for use: to describe probable and confirmed cases linked to the B.1.616 variant and to monitor the geographical expansion of this variant outside of Brittany to adapt appropriate measures.	 Physicians to report suspected B.1.616 cases to ARS (Regional health authority); investigation into these cases to be conducted by ARS and regional units of Public Health France; cases that are negative for nasopharyngeal swab but positive for deep swab are to be sent for sequencing.







Country	Institute/Author	Scope, Setting, Evidence	Surveillance Method Used	Summary of Guidance
India	Ministry of Health and Family Welfare, Government of India ⁵⁹	Scope: National Setting: Community Level of Evidence: Unclear	Population genomic screening Stated reason for use: Gather whole genome sequencing information in the community by targeting events like clustering of COVID cases, suspected super-spreader events, clustering of cases in institutions, suspected vaccine failure and re-infection clusters etc.	 The objective of the special surveillance is to gather WGS information in the community by targeting events like clustering of covid cases, suspected super-spreader events, clustering of cases in institutions, suspected vaccine failure and re-infection clusters etc. Each site to send 15 random samples every 15 days to designated lab for WGS. The samples from the tertiary care health facilities should include samples of patients with severe illness/prolonged admission, suspected re- infection, suspected vaccination failure/infection following vaccination, any other special case etc.
International	Pan American Health Association/WHO ⁶⁰	Scope: International Setting: Community Level of Evidence: Evidence informed	 Population PCR screening for both influenza and COVID-19, population genomic screening Stated reason for use: The threat of influenza epidemics and pandemics persists. It is imperative for the WHO's Global Influenza Surveillance and Response System to maintain meaningful surveillance of influenza worldwide and for countries to remain vigilant while adapting to meet COVID-19 surveillance objectives. 	 Operational considerations for surveillance of severe acute respiratory illness, and/or influenza-like illnesses using multiplex assay, including prioritization of test use; operational considerations for laboratories including clinical sample collection, storage, and transport; Multiplex assay approach including how to interpret and report results; Guidelines on testing algorithms; Influenza and COVID-19 surveillance data reporting including frequency of reporting (e.g., weekly for COVID-19 testing data) and where data should be submitted.
USA	CDC ⁶¹	Scope: National Setting: Community Level of Evidence: Unclear	Population genomic screeningStated reason for use: National and global sequencing efforts have identified changes in the SARS-CoV-2 genetic code resulting from transmission and evolution in humans and animals. These changes can affect many aspects of our response including transmission, diagnostics, therapeutics, and vaccines.	 CDC guidelines for jurisdictions to send in positive PCR samples to conduct further genomic testing, including how specimen should be collected, stored, and transported.
		Ma	rch 2021	







Country	Institute/Author	Scope, Setting, Evidence	Surveillance Method Used	Summary of Guidance
France	Sante Publique France ⁶²	Scope: National Setting: Healthcare Level of Evidence: Unclear	Population PCR screening, with sequencing of SA variant cases Stated reason for use: To track the epidemiologic characteristics of severe influenza and COVID-19 cases admitted to the ICU; to document the specific contribution of influenza and SARS-CoV-2 viruses among ICU admissions; and to describe and document the comorbidities and characteristics of patients admitted to the ICU for influenza or SARS-CoV-2 infection.	 Surveillance of severe COVID cases; All COVID cases admitted to ICU captured in SI-VIC; linked to other datasets to obtain more identifying information and track epidemiologic characteristics of the cases, describe comorbidities, and document extent of COVID contribution to ICU admissions; Centre national de référence (CNR) to sequence the cases. To be carried out by network of sentinel ICUs established in 2018; sentinel ICU to report case to regional unit of Public Health France who will conduct follow-up.
UK	Public Health England ⁶³	Scope: National Setting: Community, health care setting, long- term care Level of Evidence: Evidence informed	PCR screening, serosurveillance, hospital screening, genome sequencing Stated reason for use: To monitor coverage of the vaccine in targeted populations and identify under vaccinated groups; to rapidly detect and evaluate possible adverse events associated with vaccination; to estimate the effectiveness of the vaccine at preventing a spectrum of disease outcomes and onwards transmission in different targeted populations, and against different viral variants, as well as the duration of any protective effect; to identify risk factors for and outcomes of vaccine failure, including any impact on strain evolution; to monitor the overall impact of the vaccination programme on COVID-19 in the wider population including the indirect effect on groups not targeted by the vaccination programme; to monitor the impact of the vaccination programme on prevalence of antibodies against COVID-19 as an indicator of population level immunity, and to monitor antibody waning in the population; to monitor attitudes to vaccination and identify barriers to high vaccine uptake, and; to monitor inequalities in each of these outcome measures	 Surveillance strategies include: Routine COVID-19 testing through the Second-Generation Surveillance System (SGSS) linked to vaccination data from the NIMS to provide a dataset for monitoring vaccine effectiveness using a test-negative case control approach by vaccine, age group, clinical co-morbidities and different dosing schedules that may be used in the program. Enhanced surveillance: Once a vaccination program is implemented and the earliest eligible groups have been offered a full course of vaccination, PHE will begin enhanced surveillance of a subset of cases in vaccine eligible groups identified through the routine testing. Clinical questionnaires will be completed with the case and their GP or hospital clinician on vaccination history, past medical history, symptoms and outcomes. Repeat nose and throat swabs and acute and convalescent serum and oral fluid samples will be taken, these will be used to confirm recent infection, provide evidence of immune response following vaccination and identify







Country	Institute/Author	Scope, Setting, Evidence	Surveillance Method Used	Summary of Guidance
				 primary and secondary vaccine failures, estimate viral load, viral replication and culturable virus as markers of infectiousness, test for other respiratory viruses, and undertake sequencing to identify nucleotide changes that may favour vaccine escape and differences in phenotype. GP electronic health record studies: In addition to monitoring clinical presentations with respiratory syndromes, the network undertake sentinel swabbing of patients presenting with influenza like illness. Hospitalization and mortality rates will be monitored as surveillance of vaccine effectiveness against severe disease. Surveillance studies: number of studies have been established since the start of the pandemic with routine asymptomatic infection and these will be used to monitor vaccine effectiveness against infection: SIREN, Vivaldi, Community infection survey, and routine data
				 sources. Transmissibility will be monitored through analysis of CT values, culturable virus and duration of PCR positivity in vaccinated cases; to directly monitor the effect on transmission, a sample of cases identified through enhanced surveillance as well as healthcare workers and care home staff identified through the SIREN (Sarscov2 Immunity & REinfection EvaluatioN) study and the Vivaldi study (described below) will be recruited to monitor the effect of vaccination on their risk of onwards transmission. Routine testing data will also be used to monitor the number of secondary cases in households where the first case identified in the







Country	Institute/Author	Scope, Setting, Evidence	Surveillance Method Used	Summary of Guidance
				 household is vaccinated using the PHE HOSTED dataset with linkage to the NIMS data. Protocols for monitoring vaccine effectiveness in outbreaks in closed settings have been developed. Other surveillance methods include surveillance of vaccine failure (including follow-up with viral whole genome sequencing) and sero-surveillance (including blood donor samples, routine blood tests, and residual sera).
		Febru	lary 2021	
International	Pan American Health Association/WHO ⁶⁴	Scope: International Setting: Community Level of Evidence: Evidence informed	Population genomic screening Stated reason for use: A time series of samples is necessary to detect trends of change in genetic diversity and emerging variants. As well, appropriate number and representative samples, including unusual case samples, are important for generating reliable genomic sequencing data.	 Guidelines and criteria for sampling representative data, virologic characteristics of clinical samples, timeframe and number of SARS-CoV-2 samples. When doing genomic sequencing of samples, should consider a submission of ≥50 samples per month from varying demographic groups.
Spain	Ministry of Health – Spain ⁶⁵	Scope: National Setting: Community, health care settings, long term care, prisons Level of Evidence: Evidence informed	PCR screening, rapid antigen screening, genomic screening Stated reason for use: Early detection of cases with active SARS-CoV-2 infection; the early establishment of necessary control measures to prevent new infections; the availability of the necessary information for epidemiological surveillance, with a level of adequate disaggregation and detail.	 Genomic sequencing: to establish a surveillance of the different phylogenetic variants of COVID, its distribution, transmission and public health implications, a protocol the integrates genomic sequencing into the COVID surveillance system has been developed to detect variants. Spot screenings: targeting specific groups or populations via PCR nasopharyngeal swabs. Periodic screening: of workers and residents of health or social health centres using PCR. Systematic screening: for new admissions in health or social health centres or prior to care actions.
USA	CDC ⁶⁶	Scope: National	Serosurveillance	Using seroprevalence surveys to learn about the total number of people that have been infected, including







Country	Institute/Author	Scope, Setting, Evidence	Surveillance Method Used	Summary of Guidance
		Setting: Community Level of Evidence: Evidence informed	Stated reason for use: To better understanding how many infections with SARS-CoV-2 have occurred at different time points, in different locations, and within different populations in the US.	those infections that may have been missed. These surveys can also help estimate how much of the population has not yet been infected, helping public health officials plan for future healthcare needs.
			nuary 2021	
Europe	ECDC ⁶⁷	Scope: International Setting: Community Level of Evidence: Evidence informed	Genomic surveillance (Pre-screening RT-PCR before testing for emerging variants) Stated reason for use: To detect introduction of known variants and control the spread and impact of emerging variants.	 Systematic sequencing of a representative or random selection of detected viruses, which should be coordinated regionally and nationally. Laboratories should consider implementing pre-screening RT-PCR approaches to detect N501Y or S-gene target failure (deletion 69-70) variant viruses. All laboratories should be requested to report their results to the national public health institute that coordinates the collection of information. National public health authorities should notify cases of the variants of concern through the Early Warning and Response System (EWRS), and TESSy for case-based surveillance and aggregate reporting (which has been adapted for this purpose). To be able to confirm infection with a specific variant, sequencing of the whole SARS-CoV-2 genome, or at least the S-gene for the current variants, is required. For the VOC 202012/01, a negative S-gene result in multiplex RT-PCR assays, with positive results for the other targets, has been used as an indicator or prescreening method to identify the variant. However, it should be noted that this target failure is not exclusive to VOC 202012/01, and confirmation using sequencing is always recommended.







Country	Institute/Author	Scope, Setting, Evidence	Surveillance Method Used	Summary of Guidance
Country	Institute/Autnor	Scope, Setting, Evidence		 Summary of Guidance assess the regional correlation between S-gene target failure and VOC 202012/01 as this varies with the regionally circulating variants. If the correlation is very high, S-gene target failure can be used to approximate the frequency of VOC 202012/01. A minimum ability to roughly quantify the proportion of a variant present at a prevalence of 2.5% of the total circulating variants is recommended. This requires each country to sequence at least around 500 randomly selected samples each week. Sequencing of samples from large outbreaks and samples connected to travelers (either from point of entry screening or outbreaks involving a traveler) should be prioritized. Sequencing should be prioritized for individuals who present with a 'breakthrough infection' identified >14 days after receiving the first dose of COVID-19 vaccine (see section on Vaccination). Viral isolation of variants of SARS-CoV-2 should be carried out in P3 (Biosafety level (BSL) laboratories to prevent the accidental dissemination of a variant through laboratory exposure. In general, laboratory preparedness should be among the current high priorities, and laboratories should: 1) consider implementing diagnostic pre-screening for variants of concern (e.g. N501Y and deletion 69-70); 2) ensure human and material resources are available to manage an increasing number of requests for detection
				and characterization of SARS-CoV-2 samples; 3) increase sequencing capacity by making use of all possible sequencing capacity in the Member States







Country	Institute/Author	Scope, Setting, Evidence	Surveillance Method Used	Summary of Guidance
				from clinical, diagnostic, academic and commercial laboratories, or requesting assistance from ECDC.
France	Sante Publique France ⁶⁸	Scope: National Setting: Community, points of entry for travel Level of Evidence: Unclear	Population PCR screening, with sequencing of UK and SA variant cases Stated reason for use: To document the circulation of the UK variant and the South African variant in France and slow their spread.	 Daily monitoring of cases in individuals coming from the UK or South Africa entered into SI-DEP to identify cases coming from abroad. Any biologic material from a new probable UK or SA variant case with a CT value <25 or a confirmed case must be immediately sent to Centre National de Reference (CNR; Laboratoire de l'Institut Pasteur or Laboratoire de Lyon) for sequencing. Confirmed cases are sent to Public Health France and Centre de crise sanitaire (CCS) Surveillance geared towards variant infections in young adults, including closely monitoring infections in <30-year-olds, collecting samples in educational institutions (including PCR and antigen tests), sending positive case samples for sequencing, etc
Spain	Ministry of Health – Spain ⁶⁹	Scope: National Setting: Community Level of Evidence: Evidence informed	Population genomic screening Stated reason for use: Determine the incidence of variants of interest for public health; early identification of new variants that present increased transmissibility/virulence, vaccine breakthrough, or phenotypic change; identification of vulnerable groups associated with new variants; carry out viral phylodynamic studies.	 For the identification and monitoring of the circulating variants in the country, a procedure is proposed based on the principles: complete sequencing shall be carried out and done in a planned manner, including a representative number of cases from all AACs and a laboratory will be established. In addition to the sequencing of COVID in a representative number of cases, it is important to detect early new variants of public interests and therefore sequencing of the following cases/situations will be







Country	Institute/Author	Scope, Setting, Evidence	Surveillance Method Used	Summary of Guidance
				 indicated: suspected reinfection, suspicion of new variants of interest to public health infection, cases with suspected infection with variants that escape immunity, situations where high transmissibility or virulence is suspected. Samples used for genetic testing come from nasopharyngeal swabs.
		Dece	ember 2020	
International	WHO ⁷⁰	Scope: International Setting: Community, health care settings, sentinel sites, closed settings, travelers at points of entry Level of Evidence: Evidence informed	Nucleic acid amplification tests, antigen-detecting rapid diagnostic tests, Antibody detection (serology), reporting/epidemiological data Stated reason for use: The aim of national surveillance for COVID-19 is to enable public health authorities to reduce transmission of SARS-CoV-2, thereby limiting associated morbidity and mortality. The objectives of COVID-19 surveillance are to: Enable rapid detection, isolation, testing, and management of cases; detect and contain clusters and outbreaks, especially among vulnerable populations; identify, follow-up and quarantine contacts; guide the implementation and adjustment of targeted control measures, while enabling safe resumption of economic and social activities; evaluate the impact of the pandemic on health care systems and society; monitor longer term epidemiologic trends and evolution of SARS-CoV-2 virus and monitor trends in covid-19 deaths, and; contribute to the understanding of the co-circulation of SARS-CoV-2 virus, influenza and other respiratory viruses, and other pathogens.	 Surveillance in the community: systematic detection and reporting of events of public health significance within a community by community members. This can be through participation in contact tracing and cluster investigations. Surveillance at the primary care level: where possible, testing should be available at primary care clinics or complementary options should be available to establish dedicated SARS-CoV-2 community testing facilities, such as drive-through sites or fixed sites in community buildings. Hospital based surveillance: patients with probable or confirmed COVID-19 admitted to hospitals should be notified to national public health authorities within 24 hours of identification. Sentinel site surveillance: syndromic surveillance and collection of respiratory specimens using existing case definitions through sentinel networks. Laboratories should continue virologic testing of routine sentinel site samples for influenza, with the addition of testing samples for SARS-CoV-2. Countries are encouraged to conduct year-round sentinel surveillance for acute respiratory syndromes with testing of samples for







Country	Institute/Author	Scope, Setting, Evidence	Surveillance Method Used	Summary of Guidance
				 SARS-CoV-2. Patients selected for additional testing should preferably be representative of the population and include all ages and both sexes. Closed settings: high risk groups residing or working in closed settings is necessary to ensure the prompt detection of cases and clusters faster than through primary-care or hospital-based surveillance (prisons, residential facilities, retirement communities and care homes for persons with disabilities. Health care-associated infections: All cases and clusters in health care settings should be investigated and documented for their source and transmission patterns to allow rapid control. Mortality surveillance: number of COVID deaths occurring in hospitals should be reported daily. Laboratory surveillance: Nucleic acid amplification tests, Antigen detecting rapid diagnostic tests, antibody detection (serology). Participatory surveillance: Participatory disease surveillance enables members of the public to self-report signs or symptoms, without laboratory testing or assessment by a health care provider.
		Nove	mber 2020	
Europe	ECDC ⁷¹	Scope: International	Population rapid antigen screening	Considerations for the use of rapid antigen tests in settings of low and high infection prevalence and the
		Setting: Community, healthcare setting Level of Evidence: Evidence informed	Stated reason for use: Rapid antigen tests can offer a significant advantage over RT-PCR in terms of bringing testing closer to persons to test and timeliness of results. Benefits of rapid antigen testing include: prompt clinical management of cases with COVID-19-compatible symptoms at admission; control transmission – early detection of cases, contact tracing,	need for confirmatory testing: In a high prevalence setting, rapid antigen tests will have a high PPV. In such a situation, a positive result from a rapid antigen test (even with a lower specificity than in RT-PCR tests and thus a higher probability of false positivity) is likely to indicate a true infection and may not require







Country	Institute/Author	Scope, Setting, Evidence	Surveillance Method Used	Summary of Guidance
			population-wide testing; mitigate the impact of COVID-19 in healthcare and social-care settings: triage at admission, early detection and isolation; identify clusters or outbreaks in specific settings: early detection and isolation.	 confirmation by RT-PCROn the other hand, any negative test result should be confirmed by RT-PCR immediately or, in case of unavailability of RT-PCR, with another rapid antigen test a few days later (to allow the viral load to increase in previously false negative result). This is particularly true for asymptomatic cases with a known history of exposure. In any high-risk settings with vulnerable populations only RT-PCR should be used,unless RT-PCR capacity is limited. In vulnerable populations with symptoms, multiplex RT-PCR would be best suited for confirmation to exclude symptoms caused by other respiratory pathogens. In a low prevalence setting, rapid antigen tests will have a high NPV but a low PPV. Therefore, if used correctly, rapid antigen tests should be able to rule out a highly infectious case in such a setting. A negative test result may not require confirmation by RT-PCR, whereas a positive test will need immediate sampling for a confirmation by RT-PCR. Recurring testing by rapid antigen test every 2-3 days with the aim to identify infectious cases in a population can partly mitigate the lower sensitivity of the test and can be used in certain settings such as in staff of health care settings. In low prevalence settings, sufficient RT-PCR and logistics capacity will probably be in place to ensure a rapid turnaround of results. However, there could still be an added value to the use of rapid antigen tests because of the low cost and rapid turnaround time of analysis. Here, a careful cost-bonefit calculation has to positive test and cost positive test and cost positive test and cost positive test because of the low cost and rapid turnaround time of analysis. Here, a careful cost-bonefit calculation has to positive test and cost positive test calculation has to positive test positi test calculation has to po
				logistics capacity will probably be in place to ensure a rapid turnaround of results. However, there could still be an added value to the use of rapid antigen tests







Country	Institute/Author	Scope, Setting, Evidence	Surveillance Method Used	Summary of Guidance
				 be made in order not to exhaust the overall testing capacity in settings which have low impact on the course of the epidemic and the resources should rather be reserved for settings where highly infectious persons need to be detected. Testing in symptomatic patients: detailed guidance is provided in the document. Testing in asymptomatic patients: detailed guidance is provided in the document. Rapid antigen tests can be used for screening and serial testing (every two to three days) of residents and staff in healthcare, home care, long-term care facilities, closed settings (e.g. prisons, migrant detention and reception centres) and occupational settings in areas in which there is ongoing community transmission. Additional guidance is provided in the document.
UK	Wade et al. Summary for SAGE ⁷²	Scope: National Setting: Community Level of Evidence: Evidence informed	Wastewater surveillance Stated reason for use: Wastewater surveillance is a reliable, timely and cost-effective method to serve the needs of public health.	The English national surveillance programme samples from 44 STW, with data available since 22/07/2020, sampling a frequency of four measurements per week. Across all programmes, viral RNA data in the wastewater is being used along with complementary data, such as catchment area, sewer hydrology and sample inorganics such as ammonia and orthophosphate, to explore the relationship between SARS-CoV-2 RNA levels in STW influent and clinical cases in the population.
USA	CDC ^{73,74}	Scope: National Setting: Community	Wastewater surveillance Stated reason for use: To complement other COVID-19 surveillance indicators that inform public health actions.	 Wastewater surveillance is used to complement other COVID-19 surveillance indicators to inform public health actions. No interventions or public health actions should be solely based on wastewater data.







Country	Institute/Author	Scope, Setting, Evidence	Surveillance Method Used	Summary of Guidance
		Level of Evidence: Evidence informed		
		Aug	ust 2020	
Brazil	Ministry of Health Brazile (Ministerio de Saude) ⁷⁵	Scope: National Setting: Community Level of Evidence: Unclear	Case-based reporting and laboratory reporting of positive cases; Sentinel surveillance via Influenza sentinel surveillance network Stated reason for use : Early identification of the occurrence of COVID-19 cases; establish criteria for the notification and registration of suspected cases in health services, public and private; establish procedures for laboratory investigation; monitor and describe the pattern of morbidity and mortality from COVID- 19; monitor the clinical and epidemiological characteristics of the SARS-CoV-2 virus; establish prevention and control measures, and; carry out timely and transparent communication of the epidemiological situation in Brazil	 Surveillance objectives include: Early identification of the occurrence of COVID-19 cases Establish criteria for the notification and registration of suspected cases in health services, public and private Establish procedures for laboratory investigation Monitor and describe the patter of morbidity and mortality from COVID-19 Monitor the clinical and epidemiological characteristics of the SARS-CoV-2 virus Establish prevention and control measures Carry out timely and transparent communication of the epidemiological situation in Brazil
USA	CDC ⁷⁶	Scope: National Setting: Community Level of Evidence: Evidence informed	Hospitalization secondary to COVID-19 Stated reason for use: Coronavirus Disease 2019 Associated Hospitalization Surveillance Network (COVID-NET) is a population-based surveillance system that collects data on laboratory-confirmed COVID-19-associated hospitalizations among children and adults through a network of over 250 acute- care hospitals in 14 states. COVID-NET is CDC's source for important data, and provides important clinical information on COVID-19-associated hospitalizations, including age group, sex, race/ethnicity and underlying health conditions.	 COVID-NET is a population-based surveillance system meant to collect, analyze, and interpret data regarding lab-confirmed Covid-19-associated hospitalizations among children and adults. Cases are identified in COVID-Net if they test positive through a test ordered by a health care professional and are hospitalized within 14 days of the positive test. Clinical data collected using a standardized case reporting form by trained surveillance officers, so the data are in a standardized and uniform way. COVID-Net comprises of 99 counties in 14 states (10% of the population).
_	500.077	-	ril 2020	
Europe	ECDC ⁷⁷	Scope: International	Symptoms and population PCR screening	 In countries comprehensively testing suspected cases for COVID-19, the most accurate indicators of intensity







Country	Institute/Author	Scope, Setting, Evidence	Surveillance Method Used	Summary of Guidance
		Setting: Community, healthcare settings, long-term care Level of Evidence: Evidence informed	Stated reason for use: Monitor the intensity, geographic spread and severity of COVID-19 in the population in order to estimate the burden of disease, assess the direction of recent time trends, and inform appropriate mitigation measures; monitor viral changes to inform drug and vaccine development, and to identify markers of severe infection; monitor changes in which risk groups are most affected in order to better target prevention efforts; monitor the epidemic's impact on the healthcare system to predict the trajectory of the epidemic curve and inform resource allocation and mobilization of surge capacity as well as external emergency support; monitor the impact of any mitigation measures to inform authorities so they can adjust the choice of measures, as well as their timing and intensity; detect and contain nosocomial outbreaks to protect healthcare workers and patients, and; detect and contain outbreaks in long-term care facilities and other closed communities to protect those most at risk of severe disease and poor outcomes.	 will be the absolute number of newly confirmed cases and their notification rate per 100 000 population. Sentinel syndromic surveillance: should integrate COVID-19 surveillance with sentinel surveillance of influenza-like illness (ILI) or acute respiratory infection (ARI), which is in place in most EU/EEA Member States. The naso-pharyngeal swabs obtained by sentinel physicians from a systematic sample of patients presenting with ILI/ARI should also be tested for severe acute respiratory syndrome coronavirus 2 (SARS-CoV- 2) in addition to influenza virus and other respiratory viruses. In countries where sentinel physicians are not able to swab their patients, other approaches can be considered, such as self-swabbing and shipping of specimens using dedicated channels. Helplines, surveys, participatory surveillance. Countries not systematically testing most suspected cases while limiting physical access to primary healthcare (for example by encouraging people to call specific COVID- 19 helplines, or when people are placed in in lockdown) should consider analysing data from alternative sources. These could include phone consultations of sentinel physicians, calls to regional/national healthcare telephone helplines, consultations of online healthcare apps or self-assessment tools for advice on COVID-19 testing, or population-based participatory syndromic surveillance schemes for influenza that exist in a number of Member States. Resources permitting, countries can also conduct their own regular telephone surveys.







Country	Institute/Author	Scope, Setting, Evidence	Surveillance Method Used	Summary of Guidance
				 Virological sentinel surveillance of COVID-19 should be based on the clinical specimens obtained through national sentinel surveillance of ILI/ARI/SARI. Representative stains of virus from different geographic locations and time points, as well as from patients of both genders, and across the age and severity spectrum should be selected for sequencing in order to monitor virus evolution and changes in the virus genome. Comprehensive surveillance. Countries comprehensively testing suspected cases for COVID-19 should monitor the number and proportion of hospitalized cases, cases admitted to intensive care units (ICU) or high-dependency units (HDU), and cases with fatal outcome among the number of confirmed cases.
				 Hospital-based SARI surveillance. Countries no longer testing mild suspected cases for COVID-19 should at least test all severe acute respiratory infection (SARI) cases admitted to hospital and ICU/HDU, and monitor the proportion of confirmed COVID-19 cases among all SARI. This type of surveillance system can be comprehensive or based on a number of representative sentinel hospitals or areas. Sentinel hospitals should be selected if their catchment population is known and stable. A suitable alternative is to select all hospitals in a given area/region and use the population of that area/region as denominator. Mortality surveillance. Surveillance of hospitalized cases of COVID-19 with a focus on patient age, gender, medication, underlying







Country	Institute/Author	Scope, Setting, Evidence	Surveillance Method Used	Summary of Guidance
				conditions, smoking and healthcare worker status, as well as ICU/HDU admission and clinical outcome. Regular descriptive and multivariable analysis should inform targeted preventative measures and messages.
		Date no		
New Zealand	Ministry of Health	Scope: National Setting: Community Level of Evidence: Unclear	Wastewater surveillance Stated reason for use: Wastewater testing is being used as an extra tool to help monitor for COVID-19. Wastewater testing may be able to give us an early warning of COVID-19 cases in the community. This will help to alert local communities to be more vigilant, keep up hygiene measures, and get tested and stay home if they are unwell.	 Wastewater is collected from sites that contain a mixture of the wastewater from the toilets, sinks and drains of hundreds of thousands of people in a community. Wastewater is being sampled at least once a week from many sites around the country and the Institute of Environmental Research and Science (ESR) tests these samples at their lab to determine if they can detect the virus.